Document:

ptn_ex1031

 

Exhibit 10.31

 

Portions of this Exhibit have been redacted because they are both
(i) not material and (ii) would be competitively harmful if
publicly disclosed. Information that was omitted has been noted in
this document with a placeholder identified by the mark
“[***]”.

 

SUPPLY AGREEMENT

effective
as of 20 December 2018 ("Effective
Date")

between

AMAG Pharmaceuticals, Inc., 1100 Winter Street, Waltham, MA
02451, USA

-
"AMAG" -

and

Ypsomed AG, Brunnmattstrasse 6, CH-3401 Burgdorf,
Switzerland

-
"Ypsomed"
–

 

 

For Autoinjectors for the Administration of
Bremelanotide

Preamble

	
 

	
 

	

a)

	

Palatin
Technologies, Inc., 4-B Cedar Brook Drive, Cranbury, New Jersey
08512, USA (“Palatin”) developed a subcutaneous
injection formulation of Bremelanotide (as defined below) for use
in female sexual dysfunction;

 

	

b)

	

Palatin
licensed to AMAG the rights to develop and commercialize
Bremelanotide in North America and to manufacture Bremelanotide
worldwide;

 

	

c)

	

AMAG,
Palatin and Ypsomed have entered into a three way Confidentiality
and Non-Use Agreement, effective as of 6 March 2017 (hereinafter
“Confidentiality
Agreement”), and, under such Confidentiality
Agreement, have discussed the potential use of a customized version
of the YpsoMate (as defined below) for the injection of
Bremelanotide;

 

	

d)

	

Palatin
and Ypsomed entered into an agreement, dated as of 8 June 2012,
with respect to the variant specific customization of the YpsoMate
for the administration of pre-filled Bremelanotide syringes
(“Customization
Proposal”);

 

	

e)

	

Palatin
and Ypsomed entered into an agreement, dated as of 30 January 2015,
with respect to an industrialization project for the initializing
of the commercial supply of the customized autoinjectors
(“Industrialization
Proposal”);

 

 

 

 

 

 

	

f)

	

AMAG
and Ypsomed entered into Terms and Conditions dated 14 June 2017
governing the purchase of Component Sets (as defined therein)
pursuant to AMAG purchase order numbers 71635 and 71636 (the
“Terms and
Conditions”) and it is intended that the terms and
conditions of this Agreement will govern the supply of such
Component Sets to AMAG; and

 

	

g)

	

AMAG
and Ypsomed now wish to agree on the terms and conditions of the
commercial supply of the Components (as defined hereunder) used to
assemble the customized YpsoMate injection
device.

 

Now,
therefore, in consideration of the above, AMAG and Ypsomed agree as
follows:

 

1.    Definitions    

	
 

	
 

	

"Affiliate"

	

shall
mean any corporation or other entity that directly or indirectly
controls, is controlled by, or is under common control with AMAG or
Ypsomed, as applicable. For the purpose of this Agreement,
"control" shall mean the direct or indirect ownership of fifty
percent (50%) or more of the outstanding shares or other voting
rights of the subject entity for the election of
directors.

	

"Agreement"

	

shall
mean this Supply Agreement, together with all Appendices, as
amended or modified from time to time in accordance with the terms
hereof.

	

“Annual Minimum Quantity”

	

shall
have the meaning set forth in Appendix 3.

	

"Appendix", "Appendices"

	

shall
mean the addenda, exhibits, schedules and/or supplements to this
Agreement, as amended or modified from time to time in accordance
with the terms hereof.

	

"Applicable Laws"

	

as of
the Effective Date, Applicable Laws shall mean applicable statutes,
laws and regulations of the United States, the European Union,
Switzerland, Canada, Mexico, China, and South Korea relevant to the
services under this Agreement and the manufacture of the Components
in the Territory, and shall include, without limitation, cGMP; FDA
21 CFR Part 820; European Council Directive 93/42/EEC; ISO
13485:2003; ISO 14971:2007 and any additional, successor or
replacement statutes, laws and regulations thereto, which come into
effect during the Term of this Agreement. The statutes, laws and
regulations of additional countries or jurisdictions in the
Territory may be added to the Applicable Laws upon mutual agreement
of the Parties in accordance with Section 4.9.

	

"Authority"

	

shall
mean the Food and Drug Administration (“FDA”) (or any
successor agency thereto) in the United States, the European
Medicines Agency EMA (or any successor agency thereto) in Europe,
Health Canada in Canada, and/or the applicable equivalent
regulatory agency or entity, governmental or non-governmental,
having the responsibility, jurisdiction and authority for the grant
of Authorizations in Mexico, China, South Korea, and any other
country or jurisdiction in the Territory as mutually agreed to by
the Parties in accordance with Section 4.9.

	

"Authorizations"

	

shall
mean the authorizations for the manufacture, labeling, packaging,
importation, promotion, marketing, offer to sell, sale,
distribution and use of the Bremelanotide Devices in the Territory,
and any amendments or modifications thereto.

	

“Binding Forecast”

	

shall
have the meaning set forth in Section 7.2.

	

"Bremelanotide"

	

shall
mean Palatin’s injectable drug substance licensed to AMAG in
which the active pharmaceutical ingredient is the peptide
Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH.

 

 

 

 

 

	
 

	
 

	
 

	
 

	

"Bremelanotide Device"

	

shall
mean the customized YpsoMate for the injection of Bremelanotide
consisting of the Components, a syringe containing Bremelanotide
and accessories, if any, as such Bremelanotide Device is further
defined in the Specifications.

	

“Price Change Order”

	

shall
mean a document in the format provided in Appendix 5 provided by Ypsomed to AMAG
outlining a proposed adjustment (increase or decrease) to the
Purchase Price and the reasons for such adjustment, such document
to be reviewed and signed by both parties to enable such adjustment
to take effect.

	

"cGMP"

	

shall
mean the current Good Manufacturing Practice requirements related
to the methods used in, and the facilities and controls used for,
developing, customizing, manufacturing, testing, processing,
packaging, labeling, storing, installing, and servicing of the
Components as specified in the Medical Device Directive 93/42/EEC
and ISO 13485, as amended or modified from time to
time.

	

"Components"

	

shall
mean the individual parts and subassemblies of Ypsomed’s
customized YpsoMate, as they are described in the Specifications.
For the avoidance of doubt, Components shall not include the
syringe containing Bremelanotide.

	

"Component Set"

	

shall
mean a complete set of all Components for use by AMAG or its
designee to assemble of one Bremelanotide Device.

	

"Delivery"

	

shall
have the meaning set forth in Section 8.1.

	

“Delivery Date”

	

shall
have the meaning set forth in Section 7.4.

	

"Hidden Defect"

	

shall
mean any Component's failure (i) to have been manufactured in
accordance with this Agreement, including, without limitation, cGMP
in effect at the time of manufacture, or (ii) to conform in all
material respects to the Specifications in effect at the time of
manufacture, to the exclusion of any failure which was or could
have been identified through commercially reasonable and adequate
inspection and testing based on mutually agreed inspection criteria
as set out in the Specifications and according to Section
9.1.

	

“Initial Inspection”

	

shall
have the meaning set forth in Section 9.1.

	

"Initial Term"

	

shall
have the meaning set out in Section 21.1.

	

"Intellectual Property Rights"

	

shall
mean any and all rights in or to inventions, discoveries, know-how,
trade secrets, trade names, confidential information (including
know-how), domain names, works of authorship reduced to a tangible
medium of expression, including, without limitation, technical data
and software, industrial and other design rights, patents,
trademarks, copyrights, database rights, and any other intellectual
property, in each case, whether registered or unregistered or
patentable or not, including rights to applications or
registrations for any of the foregoing.

	

"Party", "Parties"

	

shall
mean AMAG and/or Ypsomed, as applicable.

	

“Pricing Tier”

	

shall
have the meaning set forth in Appendix 3.

	

“Purchase Order”

	

shall
have the meaning set forth in Section 7.3.

	

"Purchase Price"

	

shall
mean the prices per Component Set according to the price list as
set out in Appendix
3.

	

"Quality Agreement"

	

shall
mean the quality agreement set out in Appendix 2, as amended or modified from
time to time in accordance with the terms hereof.

	

“Rolling Forecast”

	

shall
have the meaning set forth in Section 7.2.

	

"Subsequent Term"

	

shall
have the meaning set out in Section 21.1.

 

 

 

 

 

	
 

	
 

	
 

	
 

	

"Specifications"

	

shall
mean the specifications for the Components and Component Sets, as
well as certain requirements regarding the assembly of the
Bremelanotide Device, all as further described in Appendix 1, as amended from time to
time in accordance with the terms hereof.

	

"Territory"

	

shall -
for the purpose of this Agreement - include the countries
enumerated in the definition of Applicable Laws and Authority
hereinabove; provided however that Ypsomed acknowledges that AMAG
has the right to use, register, and market the Bremelanotide Device
worldwide. Accordingly, statutes, laws and regulations of
additional countries or jurisdictions may be added to the
Applicable Laws and the respective further countries will be
included to the definition of Territory pursuant to Section
4.9.

	

" YpsoMate"

	

shall
mean the technical platform of a two-step disposable autoinjector
developed by Ypsomed for use with various drug substances contained
in a syringe.

 

	

2.

	

Appendices

 

	

2.1

	

The
following Appendices are incorporated into this Agreement by this
reference:

 

	
 

	
 

	
 

	
 

	
 

	
 

	

No.

	

Appendix

	

Subject/Content (inter alia)

	

1

	

Specifications

	

Specifications
for Component and Component Sets

	

2

	

Quality
Agreement

	

Quality
Agreement for Component Sets: change control, complaint handling,
audits, regulatory issues

	

3

	

Commercial
Terms

	

Pre-commercial
supply & capacity reservation, forecast and ordering procedure,
Purchase Prices, minimum purchase quantities

	

4

	

Price
Change Order

	

Form to
be used in the event of a change to the Purchase Price based on the
template format set out in Appendix 4.

 

	

2.2

	

Order of Precedence. The following interpretation rule shall
apply: (a) any amendments or modifications to this Agreement or the
Appendices shall prevail over this Agreement or the Appendices
themselves, (b) this Agreement shall prevail over the Appendices,
except with respect to matters relating to the quality of the
Components, the Quality Agreement shall prevail over this
Agreement, and (c) this Agreement shall prevail over the Terms and
Conditions.

 

3.    Amendments and/or
Modifications

	
 

	
 

	

3.1

	

Either
Party may at any time recommend an amendment and/or modification to
this Agreement or the Appendices, including the Specifications.
Amendments and/or modifications to this Agreement or the Appendices
shall only be effective upon a signed written agreement between the
Parties. The Appendices shall be subject to version control to
document any changes made to them. Amendments and/or modifications
to the Specifications shall be made in accordance with the change
control provisions of the Quality Agreement.

 

	

3.2

	

Neither
Party shall unreasonably withhold, condition or delay its consent
to any amendments and/or modifications recommended in good faith by
the other Party in relation to compliance with changes in
Applicable Laws, including, without limitation, cGMP, or changes in
the regulatory environment. In the event Ypsomed modifies the
YpsoMate and determines in good faith that corresponding
modifications to any Component is necessary or beneficial, then
AMAG shall approve such modifications,

 

 

 

 

 

provided
that such modifications are made in accordance with the change
control provisions of the Quality Agreement. Notwithstanding the
foregoing, with respect to each proposed amendment and/or
modification to the Agreement or the Appendices, the Parties shall
discuss in good faith the cost and time implications associated
therewith. The requirements and the procedure for change control
are set out in the Quality Agreement.

	
 

	
 

	

3.3

	

In the
event that the Parties agree to change the Specifications in
accordance with the change control provisions of the Quality
Agreement, Ypsomed shall: (x) use commercially reasonable efforts
to implement such change as soon as reasonably practicable; (y) be
responsible for ensuring that all Components manufactured following
such change meets the Specifications as amended; and (z) provide
AMAG with all information and reasonable assistance with respect to
the manufacture of the Components in connection with such change
needed to amend any regulatory filings maintained with respect to
the Bremelanotide Device. To the extent such change is a result of
a change in Applicable Law or a discretionary change requested by

[***], AMAG shall 
[***] of implementing the changes, otherwise, Ypsomed shall

[***].

	
 

	
 

	

3.4

	

The
Specifications are not physically attached to this Agreement, since
they are kept in the Design History File (DHF) which is maintained
at Ypsomed's premises. Ypsomed shall provide AMAG with a copy of
the Specifications.

 

4.    Commercial Supply

	
 

	
 

	

4.1

	

Ypsomed
shall manufacture the Component Sets in accordance with the terms
of this Agreement and the Specifications attached as Appendix
1.    

	
 

	
 

	

4.2

	

Subject
to the terms of this Agreement, AMAG shall purchase Component Sets
from Ypsomed and Ypsomed shall supply AMAG with Component
Sets.

	
 

	
 

	

4.3

	

In the
event AMAG decides during the Term of this Agreement to develop
(directly or indirectly) a new injection device for the
administration of Bremelanotide, AMAG shall give Ypsomed notice
thereof prior to issuing an invitation to tender or commencing
negotiations with any third party in respect of developing such
injection device. If, within 
[***] after AMAG gives such notice to Ypsomed, Ypsomed
requests, in writing, an opportunity to submit a proposal with
respect to the development, customization, manufacture and supply
of such injection device, AMAG shall provide Ypsomed with the
desired specifications on a confidential basis and negotiate in
good faith with Ypsomed regarding any such proposal by Ypsomed. For
the avoidance of doubt, AMAG shall be free to engage in parallel
good faith negotiations, and to enter into a definitive agreement,
with any third party with respect to the development,
customization, manufacture and supply of the new injection
device.

	
 

	
 

	

4.4

	

Ypsomed
retains all rights to promotion, import, advertisement,
distribution, offering for sale and sale in the Territory of the
YpsoMate and/or
customized variations thereof as well as other disposable injection
systems, other than the Component Sets being supplied to AMAG
pursuant to this agreement, to itself, its customers or
distributors.

	
 

	
 

	

4.5

	

The
commercial terms for the supply of Component Sets are set out in
Appendix 3.

	
 

	
 

	

4.6

	

[***] at the Purchase Price set out in Appendix 3. The Purchase Price is firm
until 
[***]. Thereafter, the Purchase Price is subject to
adjustments, however no more than on 
[***] basis, to reflect increases or decreases in raw
material prices and other related cost influencing factors that are
not under Ypsomed’s control; provided, however, that
notwithstanding the foregoing, the percentage increase or decrease
in

 

 

 

 

 

the
Purchase Price shall not exceed the lesser of (i) the percentage
increase in the 
[***] since the then-current Purchase Price was established
and (ii) 
[***]. In the event of a proposed adjustment to the Purchase
Price under this Section 4.6, Ypsomed will in good faith submit a
Price Change Order to AMAG to substantiate the adjustment, and such
adjustment shall not take effect until the Price Change Order is
signed by both Parties.

	
 

	
 

	

4.7

	

Throughout
the Term, Ypsomed agrees to use its commercially reasonable efforts
to identify and target all potential areas of cost improvement.

[***]. In the event of a proposed adjustment to the Purchase
Price under this Section 4.7, Ypsomed will in good faith submit a
Price Change Order to AMAG to substantiate the adjustment, and such
adjustment shall not take effect until the Price Change Order is
signed by both Parties.

	
 

	
 

	

4.8

	

Beginning
in 
[***], AMAG shall purchase at least the Minimum Annual
Quantity of Component Sets in each remaining calendar year during
the Initial Term as set out in Appendix 3. For the purpose of
determining whether AMAG is in compliance with this Section 4.8, a
Component Set is considered “purchased” as of the
agreed Delivery Date in the respective Purchase Order, provided
however that such ordered Component Sets will have been duly paid
by AMAG (during such calendar year or, as applicable, at a later
stage in accordance with the terms of this Agreement). If AMAG does
not purchase the Annual Minimum Quantity in a calendar year in
accordance with this Section 4.8, AMAG shall pay Ypsomed at the end
of such calendar year, upon receipt of an invoice and reasonable
supporting documentation in accordance with Section 6, an amount
equal to (a) the difference between (i) the Annual Minimum
Quantity for such calendar year and (ii) the aggregate number
of Component Sets purchased by AMAG (or its Affiliates or
licensees) during such calendar year (such amount, the
“Shortfall”),
multiplied by

[***] of the Unit Price per Component Set as set forth in
Appendix 3 (the
“Shortfall
Fee”). In the event that AMAG disputes the amount of
the Shortfall Fee due under this Section 4.8, AMAG shall provide
Ypsomed with written notice of such dispute within 
[***] of receipt of such invoice. If no written notice is
provided by AMAG within 
[***] of receipt of such invoice AMAG shall be deemed to
have given its approval to the Shortfall Fee.

	
 

	
 

	

4.9

	

The
Parties - each for its obligations under this Agreement - shall
comply with all Applicable Laws. The Parties acknowledge that AMAG
has the right to market, sell and distribute the Bremelanotide
Device in further countries than those enumerated in the definition
of Applicable Laws and Authority in Section 1 subject to and in
accordance with the terms of this Agreement. Accordingly, AMAG has
the right to reasonably request Ypsomed to comply with any
applicable laws other than the Applicable Laws as such laws are
identified and deviate from the Applicable Laws and their
requirements communicated in writing by AMAG to Ypsomed and to
adjust the term Territory under Section 1 accordingly. In the event
of any additional, successor or replacement applicable laws
affecting Ypsomed's performance under this Agreement (including,
without limitation, in respect of costs, timelines, facilities,
equipment, processes, materials or systems), Ypsomed shall have the
right to request and the Parties shall negotiate in good faith an
amendment and/or modification pursuant to Section 3. For
clarity, in the event that any additional, successor or replacement
applicable laws that AMAG wishes Ypsomed to comply with, does not
affect Ypsomed's performance under this Agreement, such additional
applicable laws shall become automatically part of the Applicable
Laws without any need for an amendment and/or modification pursuant
to Section 3.

 

 

 

 

 

	
 

	
 

	

4.10

	

The
Parties agree that the terms and conditions of this Agreement will
govern the manufacture and supply of Component Sets pursuant to
AMAG purchase order numbers 71635 and 71636, and such Component
Sets are deemed to be Component Sets manufactured by Ypsomed and
supplied to AMAG under this Agreement. In the event of a conflict
between this Agreement and the Terms and Conditions, this Agreement
shall control.

 

5.    Engagement of Subcontractors and
Designees, Final Assembly & Packaging

	
 

	
 

	

5.1

	

Ypsomed
shall be entitled to engage subcontractors in accordance with the
Quality Agreement, including (i) such subcontractors involved in
the development and manufacture of the YpsoMate platform
(“YpsoMate
Subcontractor”), and (ii) such other subcontractors
which are solely and specifically involved in the manufacture of
Component Sets under this Agreement, not being YpsoMate
Subcontractors (“Specific
Subcontractor”). The engagement of a Specific
Subcontractor by Ypsomed requires AMAG’s prior written
approval, such approval not to be unreasonably withheld,
conditioned or delayed. Ypsomed shall not be relieved from its
obligations hereunder and assumes full liability for the
performance and all acts and/or omissions of its subcontractors as
if they were its own performance and acts and/or omissions. Ypsomed
shall ensure that each subcontractor is aware of and bound by the
applicable provisions of this Agreement.

	
 

	
 

	

5.2

	

Ypsomed
shall deliver the Component Sets in bulk packaging as set out in
the Specifications (Appendix
1). AMAG shall be responsible for the final assembly and
packaging of the Bremelanotide Device. AMAG shall be entitled to
engage designees for final assembly and/or packaging of the
Bremelanotide Device, provided that AMAG shall not be relieved from
its obligations hereunder and that it assumes full liability for
the performance and all acts and/or omissions of its designees as
if they were its own performance and acts and/or
omissions.

	
 

	
 

	

5.3

	

The
Parties agree that Ypsomed and its subcontractors, and AMAG and its
designees, as applicable, may need to discuss aspects of this
Agreement with each other, (e.g., in respect of AMAG’s
designee's final assembly of the Component Set into the
Bremelanotide Device). For such purpose, Ypsomed and its
subcontractors, as applicable, on the one hand, and AMAG and its
designees, as applicable, on the other hand, may directly disclose
to, and receive from, each other confidential information of the
other Party. Each Party shall ensure that its designees or its
subcontractors, as applicable, are bound by appropriate
confidentiality obligations no less stringent than the
confidentiality obligations set out in this Agreement.

 

6.    Payment

	
 

	
 

	

6.1

	

All
costs and prices invoiced under this Agreement are specified in

[***]. All payments due to Ypsomed by AMAG under this
Agreement are expressed as net amounts and AMAG shall be liable to
pay any applicable sales taxes, value added taxes and
duties.

	
 

	
 

	

6.2

	

With
respect to each undisputed invoice under this Agreement, AMAG shall
make payments to Ypsomed under this Agreement in immediately
available funds to the bank account designated by Ypsomed from time
to time, within 
[***] after the date of the invoice.

	
 

	
 

	

6.3

	

Any
payments due hereunder which are not made within 
[***] after
the due date of such payments shall be subject to default interest
of 
[***] per 
[***] period on the unpaid amount until paid in full.
Notwithstanding any right to terminate this Agreement

 

 

 

 

 

for
AMAG's material breach as set out in Section 21.2, if any payment
due hereunder is not made within 
[***] after the date on which such payment is due, Ypsomed
shall provide written notice to AMAG, and AMAG shall use
commercially reasonable efforts to remedy such failure. If any
portion of an invoice is disputed by AMAG on justified grounds,
AMAG shall pay the undisputed amounts in accordance with the terms
above, and the Parties shall use good faith efforts to resolve
differences or discrepancies with regard to any disputed amount as
soon as practicable.

 

7.    Forecasts and Purchase
Orders

	
 

	
 

	

7.1

	

On the
Effective Date and before January 1 of each year thereafter, AMAG
shall provide Ypsomed with a written forecast for 
[***] of AMAG’s estimated requirements for Component
Sets (the "Long Range
Forecast"). Such Long Range Forecasts shall only be used for
capacity planning and determination purposes as set out
herein.

	
 

	
 

	

7.2

	

On the
Effective Date and on or before of each January 1, April 1, July 1
and October 1 during the Term, AMAG shall provide Ypsomed with a
written 
[***] rolling forecast of AMAG’s estimated
requirements for Component Sets (the "Rolling Forecast"). Such Rolling
Forecasts shall include binding and non-binding periods,

[***] (the “Binding
Forecast”). The non-binding portion of each Rolling
Forecast shall only be used for capacity planning and determination
purposes as set out herein. In its Rolling Forecast, AMAG shall, to
the extent practicable, level out potential variations in the
forecasted amounts for consecutive quarters (in any case for at
least the first 
[***] covered by the Rolling Forecast) to enable continuous
manufacture and resource planning at Ypsomed.

	
 

	
 

	

7.3

	

On or
before each January 1, April 1, July 1 and October 1 during the
Term, AMAG shall submit to Ypsomed a purchase order specifying the
number of Component Sets and the requested delivery date(s) for the
second quarter thereafter in accordance with the Binding Forecast
(“Purchase
Order”), and in each case no later than 
[***] prior to the requested delivery date(s) specified in
the Purchase Order.

	
 

	
 

	

7.3

	

In the
event of any conflict between a Purchase Order submitted by AMAG
and this Agreement, this Agreement shall prevail, unless Ypsomed
expressly approves such conflict or accepts such Purchase Order in
writing.

	
 

	
 

	

7.4

	

Ypsomed
shall acknowledge and confirm each Purchase Order in writing within

[***] of receipt, provided that AMAG has submitted the
Purchase Order in accordance with the terms of this Agreement.
However, (a) in no event shall Ypsomed be required to supply
quantities of Component Sets in excess of the Applicable Capacity
unless otherwise agreed by the Parties, and (b) if the quantity of
ordered Component Sets in a Purchase Order exceeds the quantity set
out in the Rolling Forecast by more than 
[***] for the
respective quarter, the Parties will agree on the delivery date for
such excess quantities on a case-by-case basis. If Ypsomed is
unable to deliver all of the Component Sets by the requested date
of Delivery in the Purchase Order, Ypsomed shall so notify AMAG
within 
[***] of receipt of the Purchase Order, and the Parties
shall negotiate in good faith an alternate date of Delivery as
close to the requested date of Delivery as is commercially
reasonable, provided that in no event shall such alternate date be
more than 
[***] after the requested date of Delivery in the Purchase
Order. Upon confirmation by Ypsomed, each Purchase Order will be
regarded by the Parties as a binding commitment by Ypsomed to
manufacture and Deliver to AMAG the relevant number of Component
Sets on the delivery date (such agreed upon delivery date being the
“Delivery
Date”).

 

 

 

 

 

8.    Delivery

	
 

	
 

	

8.1

	

Ypsomed
shall deliver the number of Component Sets set out in the relevant
Purchase Order by the Delivery Date (“Delivery”), provided that
over-delivery or under-delivery of up to 
[***] of the ordered amount shall be allowed. Component Sets
shall be delivered to AMAG FCA Ypsomed's manufacturing facility
indicated in the Quality Agreement (Incoterms 2010) and title shall
pass upon Delivery at such facility.

	
 

	
 

	

8.2

	

Ypsomed
shall notify AMAG of any expected delay in Delivery and will make
commercially reasonable efforts to effect Delivery as quickly as
possible. The Parties shall, if requested by AMAG, renegotiate the
date(s) of Delivery of all placed Purchase Orders following a
delayed Delivery. Ypsomed may, upon AMAG’s prior written
consent, make partial deliveries to maintain continuous supply. In
case Ypsomed anticipates that it may not be able or is unable to
Deliver all Components Sets by more than 
[***] after the Delivery Date set forth in a Purchase Order,
Ypsomed shall notify AMAG in writing immediately and provide an
explanation thereof. Ypsomed shall discuss with AMAG potential
remedies and propose as soon as reasonably possible a mitigation
plan to AMAG’s reasonable satisfaction, which will include
concrete measures in line with Ypsomed’s business continuity
plan, such as the introduction or increase of shift work, an
internal second source option, or safety stock provisions; as well
as any other measures in order to provide a fast and secure
recovery of the supply of Component Sets. Notwithstanding the
foregoing, if Ypsomed is or will be unable for any reason to
deliver all Component Sets within 
[***] of the Delivery Date in the respective Purchase Order,
then AMAG may, at its sole discretion, (i) cancel such Purchase
Order without penalty to AMAG and the number of Component Sets in
such cancelled Purchase Order shall be counted toward the Annual
Minimum Quantity for the calendar year in which the cancelled
Purchase Order was submitted, or (ii) accept Delivery of the
Component Sets on a delivery date mutually agreed to by the
Parties.

	
 

	
 

	

8.3

	

Ypsomed
will convey good title to the Component Sets to AMAG on the date of
Delivery, free and clear of any lien or encumbrance.

 

9.    Inspection, Notification of
Defects

	
 

	
 

	

9.1

	

Upon
receipt of a lot of Component Sets and all release documentation at
AMAG or its designee’s premises, AMAG or its designee acting
on behalf of AMAG shall carry out commercially reasonable and
adequate inspection and testing of the lot of Component Sets based
on mutually agreed inspection criteria as set out in the
Specifications (the “Initial
Inspection”). If any Component Sets fail Initial
Inspection, then AMAG shall notify Ypsomed within 
[***] after the arrival of such Component Sets at AMAG's or
its designee’s premises (such notice, a “Failure Notice”). If AMAG does not
so notify Ypsomed, then such Component Sets shall be deemed
accepted by AMAG. In the event AMAG rejects any Component Sets
under this Section 9.1, AMAG shall identify such Component Sets and
their date of Delivery and provide Ypsomed with a report (including
photos if applicable) on the nature of the alleged defect. AMAG
shall hold any such Component Sets for inspection by Ypsomed or,
upon Ypsomed’s written request and at 
[***] sole cost, shall return such Component Sets to
Ypsomed, whereas 
[***] shall reimburse the cost of returning such Component
Sets to Ypsomed in the event the respective Component Sets are
determined not to have failed Initial Inspection.

 

 

 

 

 

	
 

	
 

	

9.2

	

If at
any time within a period of 
[***] after Delivery of a Component Set to AMAG or its
designee AMAG discovers an alleged Hidden Defect, AMAG shall notify
Ypsomed within 
[***] after the discovery of such Hidden Defect. AMAG shall
identify the relevant Component Sets and their date of Delivery and
provide Ypsomed with a report (including photos if applicable)
describing the nature of the alleged Hidden Defect. AMAG shall hold
any such Component Set for inspection by Ypsomed or, upon
Ypsomed’s written request and at 
[***] sole cost, shall return such Component Sets to
Ypsomed, whereas 
[***] shall reimburse the cost of returning such Component
Sets to Ypsomed in the event the respective Component Sets are
determined to comply with the product warranty set out in Section
11.1. Except to the extent AMAG provides the notice of an alleged
Hidden Defect to Ypsomed in accordance with this Section 9.2, the
Delivered Component Sets shall be deemed to be accepted by
AMAG.

 

10.    Remedy and Liability for
Defects

	
 

	
 

	

10.1

	

In the
event one or more Component Sets fails Initial Inspection under
Section 9.1, has a Hidden Defect under Section 9.2, or is
determined not to comply with the product warranty set out in
Section 11.1, provided that AMAG provided proper notice to Ypsomed
within the agreed time period under Section 9.1 or Section 9.2, as
applicable, and subject to Section 11.2, as applicable, Ypsomed
shall, upon the Parties good faith decision, either (a)

[***] or, (b) 
[***]. In either case, 
[***] shall reimburse 
[***] for any applicable delivery charges. AMAG shall not
request an 
[***] as set
out under option (a) above, if the amount of defective Components
is 
[***] as set forth in Appendix 4.

	
 

	
 

	

10.2

	

In the
event the Parties are unable to agree as to whether or not a
Component Set fails Initial Inspection under Section 9.1, has a
Hidden Defect under Section 9.2, or complies with the product
warranty set out in Section 11.1, the Parties shall select an
independent laboratory which shall test such Component Set lot or
Component Sets to determine
whether such Component Set(s) fails Initial Inspection under
Section 9.1, has a Hidden Defect under Section 9.2, or complies
with the product warranty set out in Section 11.1. The findings of
such laboratory shall be binding. 
[***] upon such laboratory testing shall pay the costs
invoiced by such laboratory. During any period that the Parties are
in dispute regarding the conformity of the Component Sets, Ypsomed
shall, if requested by AMAG, replace such quantity of Component
Sets. If the laboratory determines the Component Set(s) fail
Initial Inspection under Section 9.1, has a Hidden Defect under
Section 9.2, or does not comply with the product warranty set out
in Section 11.1, then AMAG shall be entitled to the remedies set
out in Section 10.1. If the laboratory determines the Component
Set(s) passes Initial Inspection under Section 9.1, does not have a
Hidden Defect under Section 9.2, or complies with the product
warranty set out in Section 11.1, then AMAG shall pay for both the
original shipment of Component Sets and the replacement shipment of
Component Sets following such determination.

 

11.    Representations and Warranties by
Ypsomed

	
 

	
 

	

11.1

	

Product Warranty. Subject to Section 11.2, Ypsomed hereby
represents and warrants to AMAG that the Component Sets delivered
by Ypsomed to AMAG hereunder (a) will have been manufactured in
accordance with this Agreement, the Quality Agreement and
Applicable Laws, including, without limitation, cGMP in effect at
the time of manufacture, (b) will, as of the date of Delivery,
conform to the Specifications in effect at the time of manufacture,
and (c) will not be adulterated

 

 

 

 

 

within
the meaning of the U.S. Federal Food, Drug and Cosmetic Act, or any
other law in the Territory.

	
 

	
 

	

11.2

	

Warranty Limitation. The warranty under Section 11.1 and
AMAG’s remedies under Section 10 shall not apply to, and
shall be void in respect to (a) Components that have been modified
or altered in any manner by anyone other than Ypsomed or its
Affiliates or designees or authorized by Ypsomed, except that
activities carried out by AMAG or its designees in the final
assembly of a Component Set into a Bremelanotide Device in
accordance with the applicable specification, including the
Specifications, shall not be considered modified or altered under
this Section 11.2(a), or (b) defects caused by anyone other than
Ypsomed or its Affiliates or designees or authorized by Ypsomed
(i) by the use or operation of the Component Sets in an
application or environment other than that intended or recommended
for the Component Sets and/or the Bremelanotide Devices (as further
detailed in the Specifications or other separate documents such as
the Bremelanotide Device IFU); ii) by accident, negligence,
misuse or other causes other than the uses covered by this
Agreement; or (iii) by packaging, transport, warehousing,
storage or handling of the Component Sets, in any manner
inconsistent with this Agreement, including, without limitation,
the Specifications. Ypsomed expressly excludes any liability for
instructions for use for the Component Sets or Bremelanotide
Devices respectively.

	
 

	
 

	

11.
3

	

Authority & Approvals. Ypsomed represent and warrants
that (a) it has full power and authority, and has taken all
necessary actions and has obtained all necessary statutory
authorizations, licenses and approvals required, to execute and
perform this Agreement; and (b) its entry into this Agreement and
its performance of its obligations under this Agreement do not, and
will not, breach any agreements (to which it is party) with any
third party.

	
 

	
 

	

11.4

	

Regulatory Violations. Ypsomed represents and warrants that
it and its employees, agents, officers and directors have not been
debarred, disqualified or convicted of a crime for which one can be
debarred under Article 306 of the FDCA, 21 U.S.C. §335a(a) or
(b), or any equivalent foreign or local law, rule or regulation. In
the event that Ypsomed or any of its employees, agents, officers
and directors becomes so debarred, disqualified or convicted,
Ypsomed agrees to notify AMAG thereof immediately, and AMAG shall
have the right to terminate this Agreement pursuant to Section
21.2. Ypsomed further represents and warrants that it has not and
shall not knowingly use or employ in any capacity related to any
activities under this Agreement any individual, corporation,
partnership, or association which has been debarred, disqualified
or convicted of a crime for which one can be debarred under Article
306 of the FDCA, 21 U.S.C. §335a(a) or (b), or any equivalent
foreign or local law, rule or regulation. In the event that Ypsomed
becomes aware of or receives notice of the debarment,
disqualification or conviction of any such individual, corporation,
partnership, or association providing services to it which relate
to any activities under this Agreement, Ypsomed agrees to notify
AMAG immediately thereof, and AMAG shall have the right to
terminate this Agreement pursuant to Section 21.2.

 

12.    Representations and Warranties by
AMAG

	
 

	
 

	

12.1

	

AMAG
warrants that, following Delivery to AMAG or its designee, all
Component Sets shall be transported, warehoused, stored, processed,
handled and marketed by AMAG or its designees in accordance with
this Agreement, including the Specifications, and all Applicable
Laws. AMAG further warrants that it will not knowingly put on the
market any Component Sets or Bremelanotide Device with known
defects nor shall AMAG knowingly put on the market any Component
Sets or

 

 

 

 

 

Bremelanotide
Device except subject to and in accordance with the applicable
specifications, including the Specifications and
Authorizations.

	
 

	
 

	

12.2

	

AMAG
warrants that all advertising and promotional materials as well as
user manuals and other information, instructions and directions of
use relating to safety and risk issues, use, transport, handling,
and storage of the Bremelanotide Device shall comply with the
applicable specifications, and all applicable laws, rules, and
regulations in the Territory.12.3    AMAG
warrants that it will not market, offer to sell or sell any
Bremelanotide Device in any country unless and until it has all the
necessary Authorizations from the relevant regulatory agency in
such country that are required to market, offer to sell and sell
the Bremelanotide Device. Ypsomed will support AMAG in obtaining
such Authorizations in accordance with Section 14 and as set out in
the Quality Agreement.

	
 

	
 

	

12.4

	

Authority & Approvals. AMAG represent and warrants that
(a) it has full power and authority, and has taken all necessary
actions and has obtained all necessary statutory authorizations,
licenses and approvals required, to execute and perform this
Agreement; and (b) its entry into this Agreement and its
performance of its obligations under this Agreement do not, and
will not, breach any agreements (to which it is party) with any
third party.

 

	
 

	
 

	

12.5

	

Regulatory Violations. AMAG represents and warrants that is
has not been debarred under Article 306 of the FDCA, 21 U.S.C.
§335a(a) or (b), or any equivalent foreign or local law, rule
or regulation. In the event that AMAG becomes debarred, AMAG agrees
to notify Ypsomed thereof immediately, and Ypsomed shall have the
right to terminate this Agreement pursuant to Section 21.2. AMAG
further represents and warrants that it has not and shall not
knowingly use or employ in any capacity related to any activities
under this Agreement any individual, corporation, partnership, or
association which has been debarred under Article 306 of the FDCA,
21 U.S.C. §335a(a) or (b), or any equivalent foreign or local
law, rule or regulation. In the event that Ypsomed becomes aware of
or receives notice of the debarment of any such individual,
corporation, partnership, or association providing services to it
which relate to any activities under this Agreement, AMAG agrees to
notify the Ypsomed immediately thereof, and Ypsomed shall have the
right to terminate this Agreement pursuant to Section
21.2.

 

13.    Quality Management System

	
 

	
 

	

13.1

	

On or
about the date hereof the Parties shall enter into a Quality
Agreement covering the Components and Component Sets. The Parties
shall review the Quality Agreement and shall modify same from time
to time as detailed in the Quality Agreement as necessary through a
written amendment to the Quality Agreement signed by an authorized
representative on behalf of each of the Parties. The Parties shall
perform the quality control and quality assurance testing specified
in this Section 13, the Quality Agreement, the Specifications and Applicable
Laws.

	
 

	
 

	

13.2

	

Ypsomed
shall (i) maintain a quality management system, (ii) manufacture
the Component Sets and (iii) generate and maintain the compilation
of records of the manufacturing, testing, processing, packaging,
labeling, and storage of the Component Sets in accordance with the
Quality Agreement. Reference is made to Section 24.7 for the
language of such records.

	
 

	
 

	

13.3

	

Ypsomed
will participate in and support AMAG in all required actions in
respect of AMAG’s medical device vigilance systems,
including, without limitation, support in

 

 

 

 

 

respect
of initial reporting and corrective action, as set out in the
Quality Agreement or required by Applicable Law.

	
 

	
 

	

13.4

	

In
accordance with the Quality Agreement, Ypsomed shall allow AMAG
(and, if requested by AMAG, its notified body) to audit
Ypsomed’s manufacturing facilities in order to assure
compliance with this Agreement and the Quality
Agreement.

	
 

	
 

	

13.5

	

Unless
otherwise indicated, 
[***] incurred in respect of Audits pursuant to Section
13.4. All information obtained by AMAG in any Audit (including,
without limitation, the findings and results related thereto but
excluding all Confidential Information of AMAG) shall be deemed to
be Ypsomed’s Confidential Information that may not be shared
with any third parties, except as otherwise permitted under this
Agreement (which permitted uses include, for clarity, use in
regulatory filings for Authorizations, provided however that AMAG
shall not be authorized to list patents of Ypsomed in the FDA
publication entitled Approved Drug Products with Therapeutic
Equivalence Evaluations (Orange Book) without the prior written
consent of Ypsomed) or unless compulsory under Applicable
Law.

 

14.    Authorizations

	
 

	
 

	

14.1

	

AMAG
shall obtain and maintain all Authorizations for the Bremelanotide
Device and shall be the sole owner of such Authorizations in the
Territory. The costs for such applications and Authorizations shall
be borne by 
[***]. Subject to Section 14.3, as between the Parties, AMAG
shall be responsible for all communications with Authorities
regarding such Authorizations.

	
 

	
 

	

14.2

	

For the
purposes of Sections 14.3 and 14.4, AMAG shall use reasonable
efforts to notify Ypsomed in a timely manner about its application
schedule for Authorizations and any updates thereto. AMAG shall use
reasonable efforts to regularly inform Ypsomed about the expected
times for obtaining the Authorizations and notify Ypsomed in
writing about any Authorizations obtained.

	
 

	
 

	

14.3

	

Ypsomed
shall use reasonable efforts to provide AMAG or, at AMAG's request,
Authorities in the Territory with any data and information (in
English) relating to Ypsomed's performance under this Agreement,
which is necessary to apply for and/or maintain Authorizations in
the Territory.

	
 

	
 

	

14.4

	

Ypsomed
agrees to cooperate with any inspection of Ypsomed's facilities by
Authorities, including any regulatory inspection required for AMAG
to apply for and/or maintain Authorizations, in accordance with the
Quality Agreement. 

	
 

	
 

	

14.5

	

Any
provision in this Agreement, including, without limitation, in the
Quality Agreement, giving AMAG the right to access, control, check
or receive documents from Ypsomed or to visit or audit
Ypsomed’s premises, shall be interpreted as covering all
documents and information relevant to the Components but excluding
trade, operating and/or business secrets of Ypsomed and/or its
subcontractors. If documents or information containing such trade,
operating and business secrets are required for (i) AMAG's
certification by an Authority, (ii) applying for and/or maintaining
Authorizations in the Territory, (iii) risk evaluation by an
Authority or (iv) market surveillance by an Authority, the document
or information will be disclosed only to the relevant Authority.
Ypsomed shall inform AMAG of any information directly submitted to
Authorities, and Ypsomed shall be responsible for any updates and
annual reports required by such Authorities in respect of such
information.

 

 

 

 

 

	
 

	
 

	

14.6

	

[***] shall 
[***] in respect of Ypsomed's activities of providing data
and information as set out in Section 14.3, Section 14.4 and
Section 14.5, provided such costs are administrative costs of
Ypsomed. To the extent such costs relate to the Authorizations and
are not administrative costs (e.g., costs for the undertaking of
further technical studies, tests or experiments, costs for
translation of or costs for compiling additional documents),

[***] shall pay the respective costs, provided 
[***] supplies reasonable documentation substantiating such
costs, except as otherwise agreed upon in writing. For one (1)
regulatory inspection related to the Authorizations every

[***] pursuant to Section 14.4, 
[***] shall bear its own costs. 
[***] shall pay the reasonable costs incurred by

[***] for regulatory inspections in excess of one (1) every

[***] related to the Authorizations, provided 
[***] supplies reasonable documentation substantiating such
costs, except if such inspection is for-cause.

 

15.    Patient Complaints and
Recalls

	
 

	
 

	

15.1

	

The
process for resolving complaints, adverse events, and inquiries
related to the Bremelanotide Device shall be in accordance with the
Quality Agreement. As between the Parties, AMAG shall have the sole
responsibility for resolving patient questions or complaints
related to the Bremelanotide Device. Ypsomed shall refer any
patient questions and complaints (including safety and efficacy
inquiries, quality complaints and adverse event reports) that it
receives concerning the Bremelanotide Device to AMAG (together with
all available evidence and other information relating thereto) in
accordance with the Quality Agreement. Ypsomed shall not take any
further action in connection with any such patient questions or
complaints without the consent of AMAG, but shall cooperate in the
investigation and closure of any such questions or complaints at
the request of AMAG. Such assistance shall include follow-up
investigations, including testing according to Ypsomed’s SOP
and complaint handling proceedings. In addition, Ypsomed shall
provide AMAG with all information to enable AMAG to respond
properly to patient questions or complaints relating to the
Components Sets as provided in the Quality Agreement.

	
 

	
 

	

15.2

	

As
between the Parties, AMAG shall have the sole responsibility as to
whether to institute a recall or withdrawal of Bremelanotide
Devices (whether required by an Authority or instituted by AMAG for
any reason). Ypsomed shall support AMAG as set out in the Quality
Agreement. If AMAG plans a recall or withdrawal of the
Bremelanotide Device, AMAG shall notify Ypsomed promptly of the
details regarding such recall or withdrawal, including, without
limitation, providing copies of all relevant documentation
concerning such recall or withdrawal. As far as the Components are
concerned, Ypsomed shall cooperate with AMAG in any such recall and
AMAG shall reasonably consider Ypsomed’s input in respect to
the Components. Ypsomed shall provide such information in respect
of Ypsomed's performance under this Agreement as AMAG reasonably
requests or which is necessary according to Applicable Laws. All
regulatory contacts that are made and all activities concerning
such recall will be initiated and coordinated by AMAG with
Ypsomed’s involvement and assistance, as such involvement and
assistance is reasonably requested by AMAG. .

	
 

	
 

	

15.3

	

Ypsomed
shall indemnify AMAG and bear the expense and costs, including
replacements costs but not including loss of profit, resulting from
a recall or withdrawal of Bremelanotide Device to the extent caused
by a failure of the Components to comply with the product warranty
set out in Section 11.1.

 

 

 

 

 

16.    Intellectual Property
Rights

	
 

	
 

	

16.1

	

Any and
all Intellectual Property Rights in existence prior to the
Effective Date or developed during the period of this Agreement but
otherwise than in the course of performance of obligations under
this Agreement shall, as between the Parties, remain the sole and
exclusive property of the Party that brings such rights to this
Agreement.

	
 

	
 

	

16.2

	

Ypsomed
shall be the sole and exclusive owner of 
[***] (“New Ypsomed Intellectual Property
Rights”). AMAG agrees to assign and hereby assigns all of its
rights, including all patent rights, to such New Ypsomed
Intellectual Property Rights to Ypsomed, and such New Ypsomed
Intellectual Property Rights shall be included in the license in
Section 16.4. Ypsomed shall be solely entitled to legally protect
any such New Ypsomed Intellectual Property Rights and shall bear
all related costs.

	
 

	
 

	

16.3

	

AMAG
shall be the sole and exclusive owner of 
[***] (“New AMAG Intellectual Property Rights”).
Ypsomed agrees to assign and hereby assigns all of its rights,
including all patent rights, to such New AMAG Intellectual Property
Rights to AMAG. AMAG shall be solely entitled to legally protect
any such New AMAG Intellectual Property Rights and shall bear all
related costs.

	
 

	
 

	

16.4

	

Ypsomed
grants to AMAG a royalty-free, fully paid-up, irrevocable (during
the term of this Agreement), sublicensable and non-exclusive
license in respect of the Ypsomed Intellectual Property Rights and
New Ypsomed Intellectual Property Rights to the extent required for
AMAG to final assemble and pack, use, sell, offer for sale,
distribute, import and export the Components, Component Sets and
Bremelanotide Device. This limited license shall only survive an
expiration or termination of this Agreement to the extent that a
permitted use set out hereunder outlasts the expiration or
termination of this Agreements. For the avoidance of doubt, the
license shall survive expiration or termination of this Agreement
with respect to any and all Component Sets ordered or purchased as
of the date of expiration or termination until such time as the
resulting Bremelanotide Devices have been sold or have expired. The
license shall not include the right to manufacture or have
manufactured the Components.

	
 

	
 

	

16.5

	

Each
Party shall cooperate with the other in completing any patent
applications or obtaining any other patent rights relating to
Intellectual Property Rights created or developed under this
Agreement, including executing and delivering any instrument
required to assign or transfer such Intellectual Property Rights to
the other Party in accordance with Sections 16.2 or
16.3.

	
 

	
 

	

16.6

	

Ypsomed
has established a continuous standard patent surveillance in the
EU, USA and Switzerland concerning the YpsoMate. Under this
Agreement Ypsomed shall continue to undertake its continuous
standard patent surveillance concerning the YpsoMate.

 

In the
event that Ypsomed becomes aware of any third party patent rights
(granted patents) that may reasonably adversely impact AMAG’s
use of the Components in accordance with this Agreement, Ypsomed
shall notify AMAG thereof in writing without delay.

 

Ypsomed
represents and warrants that 
[***] it has
not received any claims from a third party that the YpsoMate or the
performance of the activities under this Agreement infringe or
misappropriate the rights of any third party Intellectual Property
Rights and according to Ypsomed’s assessment (of infringement
and validity) and good faith belief, 
[***], the use of the Components and Component Sets
in accordance with
this Agreement does not infringe or misappropriate any valid and
enforceable issued third party patent. If Ypsomed becomes aware of
any third party claims of patent infringement or misappropriation
(e.g., by receiving a cease and desist letter) after the Effective
Date, Ypsomed shall promptly notify AMAG thereof in
writing.

 

 

 

 

 

	
 

	
 

	

16.7

	

If
either Party becomes aware of any claim or action by a third party
claiming that the YpsoMate or the Component Sets infringes or
misappropriates a third party patent (in particular upon receipt of
a corresponding letter from such third party) (each a "Third Party Action"), such Party shall
promptly inform the other Party of such Third Party
Action.

	
 

	
 

	

16.8

	

The
defense against a Third Party Action shall be ruled as
follows:

	
 

	
 

	

a)

	

If the
Third Party Action is directed against Ypsomed for alleged
infringement of a third party patent by the YpsoMate, Ypsomed shall
defend at its sole cost the Third Party Action directed against the
YpsoMate through counsel of its choice. Ypsomed shall reasonably
update and inform AMAG on its defense strategy and the status of
any Third Party Action under this Section 16.8(a).

	
 

	
 

	

b)

	

If the
Third Party Action is 
[***] then AMAG shall have the right to defend such Third
Party Action 
[***]. The Party defending such Third Party Action shall
have the sole and exclusive right to select counsel for such Third
Party Action. The non-controlling Party shall have a reasonable
opportunity for meaningful participation in decision-making and
formulation of defense strategy. The Parties shall reasonably
cooperate with each other in all such actions or proceedings. In
the event that AMAG is enjoined from selling the Bremelanotide
Device as a result of such Third Party Action, 
[***].

	
 

	
 

	

c)

	

For
Third Party Actions under Section 16.8 (b), the Party conducting
the defense to such Third Party Action shall (i) take all
reasonable steps to prevent judgment by fault or by default being
granted in favor of the third party; (ii) ensure that the other
Party is given the right to conduct proper consultations with the
third party in relation to the claim or potential claim; (iii) if
appropriate and practicable, allow the other party to join in the
defense (including, without limitation, settlement, litigation or
appeal) of any claim; and (iv) not, without the prior written
consent of the other Party, settle or compromise any claim or
consent to the entry of any judgment that imposes any liability or
obligation upon such Party.

	
 

	
 

	

16.9

	

In the
event it is established that the Components infringe a third party
patent or if the Parties agree to settle any claim or consent to
the entry of any judgment that prevents Ypsomed to continue to
manufacture and supply the Components to AMAG, the Parties shall
mutually agree on the strategy to be followed which may contain one
of the following actions: (i) Ypsomed at its own cost shall
redesign the Components to avoid the infringement, or (ii) Ypsomed
at its own cost shall procure to obtain a license from such third
party, 
[***]. If the Parties cannot agree on either of such
actions, or if such actions are not possible or successful, the
Parties agree to discuss in good faith alternative solutions,
whereas in case such alternative solutions are not possible or
successful, the Parties agree to consensually terminate this
Agreement.

	
 

	
 

	

16.10

	

If any
Ypsomed Intellectual Property Right licensed to AMAG under this
Agreement is infringed and/or misappropriated by a third party (the
“Infringed Intellectual
Property”) the Party first having knowledge of such
infringement/misappropriation shall promptly notify the other Party
in writing.

 

 

 

 

 

17.    Disclaimer

 

Except
as expressly set out in this Agreement, neither Party makes any
warranties in respect of its activities under this Agreement,
express or implied, including, without limitation, any implied
warranty of merchantability or fitness for a particular
purpose.

 

18.    Indemnity and Insurance

	
 

	
 

	

18.1

	

Ypsomed
agrees to indemnify, defend and hold harmless AMAG, its Affiliates
and its and their respective officers, directors, employees,
subcontractors, and agents (collectively, the “AMAG Indemnitees”) against any and
all losses, damages, liabilities or expenses (including reasonable
attorney’s fees and other costs of defense) (collectively,
“Losses”) in
connection with any and all actions, suits, claims or demands that
are brought or instituted against any AMAG Indemnitee by any third
party to the extent they arise out of (a) any breach of
Ypsomed’s representations, warranties or obligations set out
in this Agreement, including but not limited to the ones set out in
Sections 11, 16.6 and 16.7, (b) any Ypsomed Indemnitees’
gross negligence or willful misconduct in performing obligations
under this Agreement, (c) a recall or withdrawal of Bremelanotide
Device in accordance with Section 15.3, or (d) 
[***] except, in each case, to the extent that such Losses
result from an action for which AMAG has an obligation to indemnify
Ypsomed under Section 18.2(a), (b) or (c).

[***].

	
 

	
 

	

18.2

	

AMAG
agrees to indemnify, defend and hold harmless Ypsomed, its
Affiliates and its and their respective officers, directors,
employees, subcontractors, and agents (collectively, the
“Ypsomed
Indemnitees”) against any and all Losses in connection
with any and all actions, suits, claims or demands that are brought
or instituted against any Ypsomed Indemnitee by any third party to
the extent they arise out of (a) the use of the Component Sets, (b)
any breach of AMAG’s representations, warranties or
obligations set out in this Agreement, (c) any AMAG
Indemnitee’s gross negligence or willful misconduct in
performing obligations under this Agreement, or (d) any claim
alleging that the manufacture, use, offer for sale, sale, import or
export of Bremelanotide infringes any Intellectual Property Rights
of a third party, except, in each case, to the extent that such
Losses result from an action for which Ypsomed has an obligation to
indemnify AMAG under Section 18.1(a), (b) or (c).

	
 

	
 

	

18.3

	

Each
Party agrees that if it is notified by a third party of any claim
or potential claim that may give rise to a right of indemnification
pursuant to Section 18.1 or Section 18.2, it shall

	
 

	
 

	

a)

	

forthwith
inform the other Party of such claim or potential
claim;

	
 

	
 

	

b)

	

take
all reasonable steps to prevent judgment by fault or by default
being granted in favor of the third party;

	
 

	
 

	

c)

	

ensure
that the other Party is given the right to conduct proper
consultations with the third party in relation to the claim or
potential claim;

	
 

	
 

	

d)

	

if
appropriate, allow the other party to join in the defense
(including, without limitation, settlement, litigation or appeal)
of any claim; and

 

 

 

 

 

 

 

	
 

	
 

	

e)

	

not,
without the prior written consent of the other Party, settle or
compromise any claim, or consent to the entry of any judgment that
imposes any liability or obligation upon such Party.

	
 

	
 

	

18.4

	

Both
Parties shall obtain and maintain for the duration of this
Agreement and a period of 
[***] thereafter
comprehensive liability insurance and other insurance all in
amounts and with coverage as required by the jurisdictions in which
they operate or as necessary to cover their obligations pursuant to
this Agreement. Each Party shall, within 
[***] of any request from the other Party, provide a copy or
extract of its certificate of insurance to the other Party
evidencing compliance with this Section.

 

19.    Limitation of Liability

	
 

	
 

	

19.1

	

To the
extent permitted by the applicable law, neither Party shall be
liable to the other Party or to any third party, under this
Agreement, in contract, tort (including negligence) or otherwise
howsoever, and whatever the cause thereof, for lost profits,
goodwill, the cost of procurement of substitute goods, the cost of
Bremelanotide or for any consequential or indirect damages,
provided, however that
such limitation shall not apply with respect to any claim arising
from (a) the gross negligence or willful misconduct of either
Party, or (b) a breach of the confidentiality provisions of Section
20. This limitation shall apply even where a Party has been
advised of the possibility of such damage and notwithstanding the
failure of the essential purpose of any limited remedy stated
herein.

	
 

	
 

	

19.2

	

To the
extent permitted by applicable laws and subject to the provisions
of this Section 19.2, either Party’s liability under this
Agreement in any calendar year shall be limited to the greater of
(a) 
[***]) and (b) the total charges paid by AMAG to Ypsomed
under this Agreement during the 
[***] period preceding the event that gave rise to the
liability, provided, however that Ypsomed’s liability over
such calendar year shall in any event be limited to 
[***]. Such limitation shall not apply with respect to any
claim arising from (a) the gross negligence or willful misconduct
of either Party, or (b) a breach of the confidentiality provisions
of Section 20.

 

It is
hereby clarified that 
[***] own costs for defending a Third Party Action pursuant
to Section 16.8 (a) or 16.8 (b) 
[***], shall not be considered as "liability" for the
purpose of calculating 
[***] liability limit pursuant to this Section
19.2.

	
 

	
 

	

19.3

	

Each
Party shall be obliged to mitigate damages.

 

20.    Confidentiality

	
 

	
 

	

20.1

	

It is
understood between the Parties that the existing secrecy
undertakings as stipulated in the Confidentiality Agreement have
been and shall remain in force with respect to information
exchanged thereunder.

	
 

	
 

	

20.2

	

For
purposes of this Agreement, “Confidential Information” includes
all information furnished by or on behalf of a Party (the
“Disclosing
Party”), its Affiliates or any of its or their
respective Representatives (as defined below), to the other Party
(the “Receiving
Party”), its Affiliates or any of its or their
respective Representatives, in respect of this Agreement or any
performance hereunder, whether furnished before, on or after the
Effective Date and furnished in any form, including written,
verbal, visual, electronic or in any other media or manner and
information acquired by observation or otherwise during any site
visit at the other Party’s facility. Confidential Information
includes all proprietary technologies, know-how, trade secrets,
discoveries, ideas, processes, formulas, samples, compounds,
extracts, inventions and any other intellectual property (whether
or not patented), analyses and compilations,
business, technical and financial information and other materials
prepared by either Party, their respective Affiliates, or any of
its or their respective representatives, containing or based in
whole or in part on any information furnished by the Discloser, its
Affiliates or any of its or their respective Representatives.
Confidential Information also includes the existence of this
Agreement and its terms.

 

 

 

 

	
 

	
 

	

20.3

	

The
Receiving Party shall maintain all Confidential Information in
trust and confidence and shall not disclose or divulge or use any
Confidential Information for any purpose other than the performance
of its obligations under this Agreement without the prior written
consent of the Disclosing Party.

	
 

	
 

	

20.4

	

The
Receiving Party may disclose Confidential Information to its
officers, directors, employees, agents, independent, consultants,
attorneys or accountants (collectively “Representatives”) only on a need
to know basis; provided that (a) such Representatives are bound by
written agreements to maintain in confidence and not use the
Confidential Information under terms at least as restrictive as the
terms of this Agreement, and (b) the Receiving Party shall be
liable for any breach by its Representatives of any obligations
hereunder.

	
 

	
 

	

20.5

	

The
foregoing obligations of confidentiality shall not apply to
Confidential Information that the Receiving Party can prove by
competent written proof:

	
 

	
 

	

a)

	

was
known to the Receiving Party prior to its receipt from the
Disclosing Party, or

	
 

	
 

	

b)

	

is
publicly available prior to receipt from the Disclosing Party or
subsequently becomes publicly available through no fault of the
Receiving Party, or

	
 

	
 

	

c)

	

is
obtained by the Receiving Party from a third party who is not under
an obligation of confidentiality and has a lawful right to make
such disclosures, or

	
 

	
 

	

d)

	

is
independently developed by or for the Receiving Party without use
of the Disclosing Party’s confidential
information.

	
 

	
 

	

20.6

	

The
Receiving Party may make disclosures required by an order of a
governmental agency, legislative body or court of competent
jurisdiction, provided that the Receiving Party: (i) provides the
Disclosing Party with immediate written notice of such requirement,
(ii) cooperates with the Disclosing Party at the Disclosing
Party’s expense in connection with the Disclosing
Party’s reasonable and lawful actions to obtain confidential
treatment for such Confidential Information, and (iii) limits such
disclosure of Confidential Information to the fullest extent
permitted under applicable law.

	
 

	
 

	

20.7

	

The
confidentiality and non-use obligations imposed by this Agreement
shall expire with respect to any particular item of a Disclosing
Party's Confidential Information on the 
[***] anniversary of the date of disclosure of such
Confidential Information.

 

21.    Term and Termination

	
 

	
 

	

21.1

	

The
term of this Agreement shall commence on the Effective Date and,
unless terminated under Sections 21.2 through 21.6, this Agreement
shall continue in full force and effect until 
[***] ("Initial
Term"). This Agreement shall be automatically renewed for
successive 
[***] year
periods (each a "Subsequent
Term" and, with the Initial Term, the “Term”) unless either Party
terminates this Agreement by 
[***] written
notice to the other Party prior to the expiration of the Initial
Term or any Subsequent

 

 

 

 

 

Term,
as applicable. 
[***] before expiration of this Agreement, the Parties shall
undertake to facilitate the phase out and wind down of the
supply.

	
 

	
 

	

21.2

	

This
Agreement may be terminated by either Party effective upon

[***] written notice to the other Party in the event of
material breach of this Agreement by the other Party, provided it
has previously given written notice of such material breach and the
breaching Party has failed to remedy such breach within

[***] of
receipt of such notice.

	
 

	
 

	

21.3

	

This
Agreement may be terminated by either Party effective immediately
upon written notice to the other Party (i) upon the institution by
or against the other Party of insolvency, receivership or
bankruptcy proceedings or any other proceedings for the settlement
of the other Party’s debts, unless such other Party timely
contests such proceedings, (ii) upon the other Party’s
making an arrangement for the benefit of creditors, or
(iii) upon the other Party’s dissolution or cessation of
business.

	
 

	
 

	

21.4

	

This
Agreement may be terminated by either Party effective upon

[***] written notice to the other Party in the event of a
change of control of the other Party if such controlling party is a
competitor of the terminating Party. For the purposes of this
Section 21.4, the term “control” shall have the same
meaning as set out in Section 1 in respect of
Affiliates.

	
 

	
 

	

21.5

	

This
Agreement may be terminated by AMAG if the Bremelanotide Device
does not receive FDA approval, provided AMAG notifies Ypsomed in
writing with 
[***] notice
that it wishes to terminate the Agreement.

	
 

	
 

	

21.6

	

This
Agreement may be terminated by AMAG if AMAG is required to withdraw
the Bremelanotide Device from the market for regulatory or health
and safety reasons, provided AMAG notifies Ypsomed in writing with

[***] notice that is wishes to terminate the
Agreement.

 

22.    Effects of Termination or
Expiration

	
 

	
 

	

22.1

	

Upon
termination by Ypsomed or receipt of notice of termination from
AMAG, Ypsomed will as soon as reasonably practicable cease
performance of the applicable activities in respect to the
Component Sets and will take reasonable steps to mitigate the
out-of-pocket expenses incurred in connection
therewith.

	
 

	
 

	

22.2

	

Each
Party shall return all documents and materials in its possession
which contain confidential information of the other Party within

[***] after termination or expiration of this Agreement,
except for copies of information that may be routinely and
automatically stored in the Party’s computer backup and
electronic communications systems. The receiving Party may retain
one copy of documents and materials which contain the disclosing
Party's confidential information for the purpose of verifying the
receiving Party's compliance with its obligations under this
Agreement or as required by Applicable Laws, but for no other
purpose whatsoever.

	
 

	
 

	

22.3

	

Sections
1, 2, 4.4, 6, 9, 10, 11, 12, 13.2(iii), 13.3, 14.3, 14.4, 14.5,
14.6, 15, 16, 17, 18, 19, 20, 22, 24.1, 24.2, 24.4, 24.5, 24.6,
24.7, 25 and 26 shall survive termination or expiration of this
Agreement.

	
 

	
 

	

22.4

	

In the
event of termination of this Agreement by Ypsomed according to
Section 21.2, 21.3 or 21.4, 
[***] shall (i) 
[***].

 

 

 

 

 

	
 

	
 

	

22.5

	

In the
event of termination of this Agreement by AMAG according to 21.5 or
21.6, 
[***] shall (i) 
[***].

	
 

	
 

	

22.6

	

In the
event of termination of this Agreement by 
[***] according to Sections 16.9, 21.2, 21.3 or 21.4,

[***].

 

23.    Force Majeure

 

Neither
Party shall lose any rights hereunder or be liable to the other
Party for damages or losses (except for payment obligations) on
account of failure of performance by the defaulting Party if the
failure is occasioned by war, strike, acts of terrorism, fire, acts
of god, earthquake, flood, lockout, embargo, governmental acts or
orders or restrictions or any other similar reason where failure to
perform is beyond the reasonable control of and could not
reasonably have been expected to occur by the defaulting Party and
such Party has exerted all reasonable efforts to avoid or remedy
such force majeure. Failure to obtain, or revocation of, one or
more Authorizations shall not be considered an event of force
majeure.

 

24.    Miscellaneous

	
 

	
 

	

24.1

	

Entire Agreement. This Agreement, including its Appendices,
together with the Confidentiality Agreement, set forth the entire
agreement and understanding of the Parties in respect of the
subject matter hereof, and supersedes all prior discussions,
agreements and writings relating thereto.

	
 

	
 

	

24.2

	

Independent Contractors. The relationship of the Parties
hereto is that of independent contractors. The Parties are not
deemed to be agents or partners nor are they engaged in a joint
venture for any purpose as a result of this Agreement or the
transactions contemplated herein.

	
 

	
 

	

24.3

	

Assignment. Except as otherwise expressly provided herein,
the Parties agree that their rights and obligations under this
Agreement shall not be delegated, transferred or assigned to a
third party without the prior written consent of the other Party;
provided either Party may assign this Agreement or parts thereof to
its Affiliates, without the other Party's consent. Subject to
Section 21.4, either Party may assign this Agreement in its
entirety, without the other Party’s consent, to a successor
to substantially all of the business or assets of the assigning
Party. This Agreement shall be binding upon and inure to the
benefit of the Parties and their successors and permitted
assigns.

	
 

	
 

	

24.4

	

Severability, Waiver. In the event that any provisions of
this Agreement are determined to be invalid or unenforceable by a
court of competent jurisdiction, the remainder of this Agreement
shall remain in full force and effect without said provision. The
Parties shall in good faith negotiate a substitute clause for any
provision declared invalid or unenforceable, which shall most
nearly approximate the intent of the Parties in entering this
Agreement, or will leave the provision unreplaced by mutual
consent. Any provision of this Agreement held invalid or
unenforceable only in part or degree will remain in full force and
effect to the extent not held invalid or unenforceable. The failure
of a Party to enforce any provision of this Agreement shall not be
construed to be a waiver of the right of such Party to thereafter
enforce that provision or any other provision or
right.

	
 

	
 

	

24.5

	

Notices. Any required notices hereunder shall be given in
writing and sent by (a) facsimile or electronic mail
transmission (receipt verified), (b) recognized overnight courier,
freight prepaid, specifying next-day delivery, with written
verification of receipt

 

 

 

 

or (c)
priority mail, postage prepaid, with written verification of
receipt, in each case, to the address of the applicable Party
below, or to such other address as such Party may substitute by
written notice.

 

If to
AMAG:

AMAG
Pharmaceuticals, Inc.

1100
Winter Street

Waltham,
MA 02451

USA

 

Attention:
VP, Technical Operations

Fax:

 

with a
copy to:

Attention:
General Counsel

Fax:

 

 

If to
Ypsomed:

 

Ypsomed
AG

Brunnmattstrasse
6

CH-3401
Burgdorf

Switzerland

 

Attention:
General Counsel

Fax:
+41 (34) 424 41 55

 

With a
copy to:

Attention:
Product and Account Manager AMAG 

 

Either
Party may change its address for communications by a notice to the
other Party in accordance with the terms of this Section
24.5.

	
 

	
 

	

24.6

	

No Use of Name. Neither AMAG nor Ypsomed shall be permitted
to use the name of the other Party in any publicity, advertising or
public announcement concerning this Agreement or the subject matter
hereof without the prior express written consent of the other Party
except to the extent required by law. As soon as the Bremelanotide
Device is in the market, Ypsomed shall be allowed to mention AMAG
in its clients list and to show the Component Set (assembled with a
syringe of placebo) in trade fairs, exhibitions and
publications.

	
 

	
 

	

24.7

	

English Language. This Agreement has been prepared in the
English language and the English language shall control its
interpretation. All notices required or permitted to be given
hereunder, and all written or other communications between the
Parties regarding this Agreement or pursuant to this Agreement,
shall be in the English language, unless otherwise stated herein.
AMAG acknowledges that parts of the technical and quality
documentation for the Component Sets and the documentation of
Ypsomed's business activities are in the German
language.

 

 

 

 

 

25.    Arbitration and Governing
Law

 

	
 

	
 

	

25.1

	

Disputes. The Parties will try to settle their differences
amicably between themselves. If any claim, dispute, or controversy
of whatever nature arising out of or relating to this Agreement,
including the performance or alleged nonperformance of a Party of
its obligations under this Agreement arises between the Parties
(each a “Dispute”), a Party will, before
initiating any proceedings pursuant to Section 6(c), notify the
other Party in writing of such Dispute. If the Parties are unable
to resolve the Dispute within 
[***] of receipt of the written notice by the other Party,
such dispute will be referred to an executive officer of AMAG and
an executive officer of Ypsomed, or their designees, who will meet
in person at least once and use their good faith efforts to resolve
the Dispute within 
[***] after such referral.

	
 

	
 

	

25.2

	

Arbitration. If a Dispute is not resolved as provided in
Section 25.1, whether before or after expiration or termination of
these Terms and Conditions, the Parties hereby agree that such
Dispute will be resolved by final and binding arbitration conducted
in accordance with the 
[***]. The arbitration will be held in 
[***]. The governing law of this Agreement will govern any
such proceedings. The arbitration will be conducted by a panel of
three (3) arbitrators with significant experience in the
pharmaceutical manufacturing industry, unless otherwise agreed by
the Parties, appointed in accordance with applicable 
[***]. Any arbitration herewith will be conducted in the
English language to the maximum extent possible. The arbitrators
will be instructed not to award any punitive or special damages and
will render a written decision no later than 
[***] following the selection of the arbitrators, including
a basis for any damages awarded and a statement of how the damages
were calculated. Any award will be promptly paid in U.S. dollars
free of any tax, deduction or offset. Each Party agrees to abide by
the award rendered in any arbitration conducted pursuant to this
Section 6. With respect to money damages, nothing contained herein
will be construed to permit the arbitrator or any court or any
other forum to award punitive or exemplary damages. By entering
into this agreement to arbitrate, the Parties expressly waive any
claim for punitive or exemplary damages. Each Party will pay its
legal fees and costs related to the arbitration (including witness
and expert fees). Judgment on the award so rendered will be final
and may be entered in any court having jurisdiction
thereof.

	
 

	
 

	

25.3

	

Governing
Law. This Agreement and any dispute arising therefrom shall be
governed by and construed in accordance with the laws of

[***], regardless of the conflict of laws principles of that
or any other jurisdiction. The UN Convention on Contracts for the
International Sale of Goods is not applicable to this
Agreement.

	
 

	
 

	

25.4

	

Nothing
in this Section 25 will preclude either Party from seeking
equitable relief or interim or provisional relief from a court of
competent jurisdiction, including a temporary restraining order,
preliminary injunction, specific performance or other interim
equitable relief, concerning a Dispute either prior to or during
any arbitration if necessary to protect the interests of such Party
or to preserve the status quo pending the arbitration
proceeding.

	
 

	
 

	

26.

	

Securities Laws. The parties hereby acknowledge that AMAG is
publicly traded on the NASDAQ National Market System under the
symbol "AMAG" and Ypsomed is publicly traded on the Swiss
Performance Index (SPI) of SIX Swiss Exchange.  Further, each
party is aware and will advise its Representatives who are informed
of matters that are the subject of this Agreement, of the
restrictions imposed by certain applicable securities laws on the
purchase or sale of securities by any person who has received or
had access material, nonpublic information concerning a company and
on the communication of such information to any other person when
it is  reasonably
foreseeable that such person is likely to purchase or sell such
securities in reliance on such information.

 

 

 

 

 

 

In
witness whereof, AMAG and Ypsomed have executed this Agreement in
two originals, one for each Party, by their respective duly
authorized representatives.

 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

AMAG
Pharmaceuticals, Inc.  

	
	

Ypsomed
AG  

	

Date:

	

December
21, 2018

	
 

	

Date:

	

January
25, 2019

	

By:

	

/s/
William K. Heiden

	
 

	

By:

	

/s/
Ulrike Bauer

	

Print
Name:

	

William
K. Heiden

	
 

	

Print
Name:

	

Ulrike
Bauer

	

Title:

	

President
and CEO

	
 

	

Title:

	

SVP
Marketing and Sales Delivery Systems

	
 

	
 

	
 

	

By:

	

/s/
Frank Mengis

	
 

	
 

	
 

	

Print
Name:

	

Frank
Mengis

	
 

	
 

	
 

	

Title:

	

COO

 

 

 

 

 

 

 

Appendix
1

Specifications
for Components

 

The
Specifications for the Components are kept in the Design History
File (DHF), which is maintained at Ypsomed's premises.

 

 

 

 

 

 

 

 

Appendix
2

Quality
Agreement

 

Separate
Document.

 

 

 

 

 

 

 

 

Appendix
3

Commercial
Terms

 

	
 

	
 

	

1.

	

Applicable
Capacity & Contribution

	
 

	
 

	

1.1

	

Ypsomed
will invest in the entire production infrastructure required to
produce the Components, including high-cavity tooling and fully
automatic assembly equipment.

 

Pursuant
to the terms of the Industrialization Proposal, 
[***] partially financed the manufacturing capacity build-up
through upfront payments as set out in the Industrialization
Proposal.

	
 

	
 

	

1.2

	

AMAG
and Ypsomed will determine the required manufacturing capacity that
Ypsomed will reserve for AMAG based on AMAG’s Long Range
Forecast delivered by AMAG to Ypsomed in accordance with Section
7.1 of the Supply Agreement. It is agreed between the Parties that
the applicable manufacturing capacity per calendar year
(“Applicable
Capacity”) will be determined in accordance with this
Section 1.2. The initial Applicable Capacity is 
[***] Component Sets. The Applicable Capacity may be
adjusted, from time to time upon either Party’s written
request, based on the Long Range Forecast. In the event AMAG
requests an increase in the Applicable Capacity that requires
Ypsomed to invest in additional production infrastructure, such
change shall be possible provided AMAG notifies Ypsomed at least

[***] prior
to such requested increase. In the event AMAG or Ypsomed in good
faith requests a decrease in the Applicable Capacity, such change
shall be possible provided that the Party requesting such decrease
notifies the other Party at least 
[***] prior to such requested decrease. Each change of the
Applicable Capacity shall be agreed upon by the Parties in good
faith. In the event AMAG’s capacity demand according to the
Long Range Forecast exceeds 
[***] Component
Sets per calendar year, the parties shall negotiate in good faith
the terms upon which Ypsomed will expand its manufacturing capacity
to accommodate AMAG’s increased capacity demand. In the event
AMAG’s capacity demand according to the Long Range Forecast
exceeds 
[***] Component Sets per calendar year (i.e., a commitment
for Applicable Capacity above 
[***] but not
more than 
[***] Component Sets) AMAG shall pay Ypsomed a capacity
contribution fee of 
[***]) as follows upon receipt of an invoice from
Ypsomed:

 

	
 

	
 

	
 

	
 

	

Payment Milestones (Contribution for Applicable Capacity
from [***] to [***] Component
Sets) 

	

Amount in [***]

	

[***] prior
to the planned change of Applicable Capacity (i.e. date of request
for additional capacity above 
[***] Component Sets per calendar year)

	

[***]

	

[***] prior
to the planned change of Applicable Capacity (i.e. 
[***] after
date of request for additional capacity above 
[***] Component
Sets per calendar year)

	

[***]

	

[***] prior
to the planned change of Applicable Capacity (i.e. 
[***] after
date of request for additional capacity above 
[***] Component Sets per calendar year)

	

[***]

	

Total

	

[***]

	
 

	
 

	

2.

	

Minimum
Purchase Quantity

 

In
accordance with Section 4.8 of the Supply Agreement, beginning in
2019 AMAG shall purchase at least the Annual Minimum Quantity of
Component Sets in each calendar year during the Term as
set forth below. For the purpose of determining whether AMAG is in
compliance with Section 4.8 of the Agreement, a Component Set is
considered “purchased” as of the agreed Delivery Date
in the respective Purchase Order, provided however that such
ordered Component Sets will have been duly purchased and paid by
AMAG (during such calendar year or, as applicable, at a later stage
in accordance with the terms of this Agreement).

 

 

 

 

	
 

	
 

	
 

	
 

	

Units

	

Minimum
Purchase Quantity

	

Per
Purchase Order

	

[***] (the “Minimum Batch Size”)

	

Initial
Term

	

[***] Component Sets per each calendar year during the
Initial Term beginning in 
[***] (the “Annual Minimum
Quantity”)

	

Subsequent
Term(s)

	

The
Annual Minimum Quantity for the Subsequent Term(s) shall be
determined and mutually agreed upon by the Parties prior to the end
of the Initial Term or of each Subsequent Term, as applicable. If
the Parties cannot agree on the Annual Minimum Quantity for a
Subsequent Term prior to beginning of such Subsequent Term, AMAG
shall be obligated to purchase, in each calendar year during the
Subsequent Term, no less than the Annual Minimum Quantity for the
last full calendar year

 

	

3.

	

Purchase
Price

 

The
invoiced Purchase Price for Component Sets applied to all invoices
during a calendar year will be determined based on number of
Component Sets for the respective calendar year as set forth in the
Binding Forecast and as determined according to the following
Pricing Tiers:

 

Pricing Tiers

	
 

	
 

	
 

	
 

	

Annual Quantity of Component Sets

	

Unit Price per Component Set in 
[***]

	

[***]

	

[***]

	

[***]

	

[***]

	

[***]

	

[***]

	

[***]

	

[***]

	

[***]

	

[***]

	

[***]

	

[***]

 

The
Purchase Price includes the costs for bulk packaging (bulk
packaging as set out in Appendix
2).

 

The
effective Unit Price per Component Set shall be determined based on
the total number of Component Sets ordered by AMAG for the
respective calendar year accordance with Section 7.3, provided
however that such ordered Component Sets will have been duly
purchased and paid by AMAG (during such calendar year or, as
applicable, at a later stage in accordance with the terms of this
Agreement).

 

Accordingly,
within 
[***] after the end of each calendar year during the Term,
Ypsomed shall calculate the total amount of ordered Component Sets
duly purchased and paid by AMAG and shall perform a
“True-Up”
reconciliation and shall provide AMAG with a written report of such
reconciliation. If the True-Up report shows that a difference in
the number of Component Sets purchased by AMAG compared to the
pricing tier serving as basis for the invoiced Purchase Price in
such calendar year results in either an underpayment or an
overpayment between
the Parties, the Party owing payment to the other Party shall pay
the amount of the difference to the other Party within 
[***] of the
date of delivery of such True-Up report.

 

 

 

 

 

	
 

	
 

	

4.

	

Invoicing

 

Ypsomed
shall submit an invoice to AMAG upon each Delivery of Component
Sets. The term of payment is 
[***] from
the date of invoice.

	
 

	
 

	

5.

	

Delivery

	
 

	
 

	

5.1

	

Ypsomed
shall deliver the Component Sets in accordance with Section 8 of
the Agreement and the shipping procedures set out in the
Specifications.

	
 

	
 

	

5.2

	

All
Component Sets shall be delivered to AMAG FCA Ypsomed's
manufacturing facility (Incoterms 2010).

 

 

 

 

Appendix 4

Price Change Order

 

Price Change Order – [insert
number]

                

Dated:
[insert
date]

 

This is
a Price Change Order of the purposes of Supply Agreement between
Ypsomed AG and AMAG Pharmaceuticals, Inc. dated
_________________[insert
date] (the “Agreement”).

 

Terms
used but not defined in this Price Change Order shall have the
meaning given to them in the Agreement.

 

Effective
Date:    Day, Month, Year

End
Date:    Day, Month, Year

 

Current
Purchase Price: $

 

Revised
Purchase Price: $

 

New
Total Cost (if applicable): $

 

The
following reasons have caused the Purchase Price to change
(increase or decrease):

 

	
 

	
 

	

1.

	
 

EXECUTED as an AGREEMENT

 

	
 

	
 

	
 

	
 

	

Signed
by

YPSOMED AG

 

___________________________

Signature

 

___________________________

Name

 

___________________________

Title

 

___________________________

Date

	

Signed
for and on behalf of

AMAG PHARMACEUTICALS, INC.

 

___________________________

Signature

 

___________________________

Name

 

___________________________

Title

 

___________________________

DateExhibit 10.1

 

EXECUTION COPY

 

SEPARATION AGREEMENT AND GENERAL
RELEASE

 

SEPARATION
AGREEMENT AND GENERAL RELEASE between MDC Partners Inc. (“MDC” or the “Company”)
and Jonathan Mirsky (“Executive”) dated as of September 22, 2020 (this “Agreement and Release”).

 

WHEREAS, Executive
is General Counsel and Corporate Secretary of the Company pursuant to an Employment Agreement dated as of May 6, 2019 (the
 “Employment Agreement”);

 

WHEREAS, MDC and Executive
intend to terminate their relationship of employee and employer on the mutually agreed terms and conditions set forth below; and

 

NOW, THEREFORE, in
consideration of the mutual covenants herein contained, the parties agree as follows:

 

1.            Termination
of Employment. By mutual agreement, Executive and MDC have determined that Executive’s employment with the Company
will terminate at the close of business on September 30, 2020 (the “Termination Date”). During the period
of time from the date hereof until the Termination Date, the Executive will cooperate in good faith with a newly-appointed General
Counsel and Corporate Secretary on an appropriate transition of duties and responsibilities to the benefit of the Company. For
the avoidance of doubt, the Executive shall cease using the title of General Counsel and Corporate Secretary effective immediately.

 

2.            Severance
Payments. Subject to Executive’s execution and non-revocation of, and compliance with, this Agreement and Release,
and execution and non-revocation of the release set forth in Exhibit A hereto, MDC shall pay to Executive the
following amounts (collectively, the “Severance Payments”):

 

		a.	An amount equal to (i) Executive’s accrued but unpaid base salary and perquisite allowance
through the Termination Date and (ii) reimbursement for any unpaid reimbursable business expenses incurred in the course of
his employment through the Termination Date, in each case in accordance with MDC’s regular payroll and expense reimbursement
practices;

 

		b.	An aggregate amount equal to $275,000, representing six (6) months of Executive’s base
salary, subject to required federal, state and local tax withholdings by MDC, to be paid in a cash lump-sum not later than 60 days
following Termination Date; and

 

		c.	Not later than 60 days after the Termination Date, MDC will pay Executive an additional amount
in respect of accrued and unused vacation days in 2020 under MDC’s current policy.

 

     

     

    

 

3.            Outstanding
Inducement and Incentive Awards. Subject to Executive’s execution and
non-revocation of, and compliance with, this Agreement and Release, and execution and non-revocation of the release set forth in
Exhibit A hereto, Executive’s outstanding inducement and incentive awards shall be treated as follows
(collectively, the “Vesting Entitlements”):

 

		a.	Effective on the Termination Date, 166,666 unvested and outstanding restricted shares of MDC Class A
stock previously granted to him pursuant to that certain Restricted Stock Grant Agreement dated June 26, 2019 shall be deemed
fully vested;

 

		b.	Effective on the Termination Date, 166,666 unvested and outstanding stock appreciation rights in
respect of MDC Class A stock previously granted to him pursuant to that certain Stock Appreciation Rights Agreement dated
June 26, 2019 shall be deemed fully vested and exercisable;

 

		c.	Executive shall remain eligible to vest in restricted shares granted pursuant to the terms and
conditions of that certain Restricted Stock Agreement between MDC and Executive dated as of November 4, 2019 (the “LTIP
Stock Award”). Executive acknowledges and agrees that stock vesting under the LTIP Stock Award, if any, shall be calculated
and prorated based on a service period equal to 12.5% of the vesting period, notwithstanding Executive’s termination without
 “Cause” as of the Termination Date or any subsequent event under the relevant plan or grant agreement (so that the
maximum number of shares eligible to vest pursuant to the LTIP Stock Award is 15,125). The final number of shares vested under
the LTIP Stock Award, if any, will be issued on the date specified in the underlying award agreement and shall also be conditioned
upon and subject to Executive’s ongoing compliance with the terms and conditions of this Agreement and Release following
the Termination Date; and

 

		d.	Executive shall remain eligible to receive a cash payout from MDC pursuant to the terms and conditions
of that certain Award Agreement between MDC and Executive dated as of November 4, 2019 (the “LTIP Cash Award”).
Executive acknowledges and agrees that payment of the amount due under the LTIP Cash Award, if any, shall be calculated and prorated
based on a service period equal to 12.5% of the performance period, notwithstanding Executive’s termination without “Cause”
as of the Termination Date or any subsequent event under the relevant plan or grant agreement (so that the maximum amount he is
eligible to receive pursuant to the LTIP Cash Award is $60,500 (i.e. in the event the “EBITDA Performance Multiplier”
is ultimately determined to be 2)). Payment by MDC of the final amount due under the LTIP Cash Award, if any, will be made on the
payment date specified in the underlying award agreement and shall also be conditioned upon and subject to Executive’s ongoing
compliance with the terms and conditions of this Agreement and Release following the Termination Date.

 

    2

     

    

 

4.            No
Further Entitlements. Except as otherwise set forth in this Agreement and Release,
the Executive is not entitled to any further compensation or benefits from MDC, including without limitation any bonus payment
with respect to calendar year 2020. The Executive expressly acknowledges and agrees that except as set forth in this Agreement
and Release, he has been paid all compensation of any kind to which he is entitled as a result of his employment with MDC. Executive
further acknowledges and agrees, and represents and warrants, that he does not own or have any right to any stock, stock appreciation
rights or other equity in MDC, except for (a) the Vesting Entitlements, (b) 44,084 Class A shares previously vested
and/or purchased in the open market and (c) 83,334 previously vested stock appreciation rights with a strike price of $5.00.

 

5.            Release
of Claims by Executive. By signing this Agreement and Release, Executive, on behalf of himself and his current, former,
and future heirs, executors, administrators, attorneys, agents and assigns, releases and waives all legal claims in law or in equity
of any kind whatsoever that Executive has or may have against MDC, its parents, subsidiaries and affiliates, and their respective
officers, directors, employees, shareholders, members, agents, attorneys, trustees, fiduciaries, representatives, benefit plans
and plan administrators, successors and/or assigns, and all persons or entities acting by, through, under, or in concert with any
or all of them (collectively, the “Released Parties”). This release and waiver covers all rights, claims, actions
and suits of all kinds and descriptions that Executive now has or has ever had, whether known or unknown or based on facts now
known or unknown, fixed or contingent, against the Released Parties, occurring from the beginning of time up to and including the
date that Executive executes this Agreement and Release, including, without limitation:

 

a.            any
claims for wrongful termination, defamation, invasion of privacy, intentional infliction of emotional distress, or any other common
law claims;

 

b.            any
claims for the breach of any written, implied or oral contract between Executive and MDC;

 

c.            any
claims of discrimination, harassment or retaliation based on such things as age, national origin, ancestry, race, religion, sex,
sexual orientation, or physical or mental disability or medical condition;

 

d.            any
claims for payments of any nature, including but not limited to wages, overtime pay, vacation pay, severance pay, commissions,
bonuses and benefits or the monetary equivalent of benefits, but not including any claims for unemployment or workers’ compensation
benefits, or for the consideration being expressly provided to Executive pursuant to this Agreement and Release; and

 

e.            all
claims that Executive has or that may arise under the common law and all federal, state and local statutes, ordinances, rules,
regulations and orders, including but not limited to any claim or cause of action based on the Fair Labor Standards Act, Title VII
of the Civil Rights Act of 1964, the Age Discrimination in Employment Act, the Family and Medical Leave Act, the Americans with
Disabilities Act, the Civil Rights Acts of 1866, 1871 and 1991, the Rehabilitation Act of 1973, the National Labor Relations Act,
the Executive Retirement Income Security Act of 1974, the Worker Adjustment and Retraining Notification Act, the Vietnam Era Veterans'
Readjustment Assistance Act of 1974, Executive Order 11246, and any state laws governing employee rights, as each of them has been
or may be amended.

 

    3

     

    

 

This Agreement and Release shall be binding
upon and inure to the benefit of Executive and the Released Parties and any other individual or entity who may claim any interest
in the matter through Executive. Executive also acknowledges that he has not assigned any of his rights to make the aforementioned
claims or demands.

 

By way of further clarification, Executive
shall not be entitled to receive any of the Severance Payments or Vesting Entitlements under this Agreement and Release unless
Executive executes and delivers to the Company the Release of Claims in the form of Exhibit A hereto upon or
following the Termination Date.

 

6.            Attorney
Review; Review Period; Revocation Period. Executive is hereby advised that he should
consult with an attorney prior to executing this Agreement and Release. Executive is also advised that he has twenty-one (21) days
from the date this Agreement and Release is delivered to him within which to consider whether he will sign it. If Executive signs
this Agreement and Release, he acknowledges that he understands that he may revoke this Agreement within seven (7) days after
he has signed it by notifying MDC in writing that he has revoked this Agreement. Such notice shall be addressed to David Ross,
Executive Vice President, c/o MDC Partners Inc., 330 Hudson Street, 10th Floor, New York, NY 10013. This Agreement shall
not be effective or enforceable in accordance with its terms until the 7-day revocation period has expired.

 

7.            Intellectual
Property Rights. Executive acknowledges and agrees that all concepts, writings and proposals submitted to and accepted
by MDC (“Intellectual Property”) which relate to the business of MDC and which have been conceived or made by him during
the period of his employment, either alone or with others, are the sole and exclusive property of MDC. As of the date hereof, Executive
hereby assigns in favor of MDC all the Intellectual Property covered hereby. On or subsequent to the date hereof, Executive shall
execute any and all other papers and lawful documents required or necessary to vest sole rights, title and interest in MDC or its
nominee of the Intellectual Property.

 

8.            Non-Admission.
This Agreement and Release shall not in any way be construed as an admission by MDC of any liability for any reason, including,
without limitation, based on any claim that MDC has committed any wrongful or discriminatory act.

 

9.            Mutual
Non-Disparagement. Executive agrees that he will not say, write or cause to be said or written any statement that may be
considered defamatory, derogatory or disparaging of any of the Released Parties. MDC agrees to use commercially reasonable efforts
to cause its senior executives to not say, write or cause to be said or written, any statement that may be considered defamatory,
derogatory or disparaging of the Executive.

 

    4

     

    

 

10.            Confidentiality;
Return of Company Property; Cooperation. Executive agrees to keep the terms
and the existence of this Agreement and Release confidential and not to discuss it with anyone other than his attorney, tax advisor
or as may be required by law. Executive covenants that he will return all MDC documents, files, equipment and other property in
his possession to MDC on or prior to the Termination Date and represents
and warrants that he has not retained any copies or excerpts of any MDC documents or files. The Executive agrees that he will not
encourage or cooperate or otherwise participate or confer with any current or former employee of MDC or any other of the Released
Parties, or any potential plaintiff, to commence any legal action or make any claim against MDC or any other of the Released Parties
with respect to such person’s employment with MDC or any other of the Released Parties; provided, however, that nothing in
this Agreement and Release shall prohibit Executive from cooperating with any government agency. The Executive will cooperate with
MDC and its counsel in connection with any investigation, administrative proceeding or litigation relating to any matter in which
Executive was involved or of which he has knowledge as a result of his employment with MDC.

 

11.            Entire
Agreement; No Other Promises. Except as to any confidentiality, non-compete and/or non-solicitation agreements signed by
Executive upon or during his employment with MDC, Executive hereby acknowledges and represents that this Agreement and Release
contains the entire agreement between Executive and MDC, and it supersedes any and all previous agreements concerning the subject
matter hereof. Executive further acknowledges and represents that neither MDC nor any of its agents, representatives or employees
have made any promise, representation or warranty whatsoever, express, implied or statutory, not contained herein, concerning the
subject matter hereof, to induce Executive to execute this Agreement and Release, and Executive acknowledges that he has not executed
this Agreement and Release in reliance on any such promise, representation or warranty.

 

12.            Confirmation
of Restrictive Covenants. Executive hereby acknowledges and reaffirms all of his restrictive covenants set forth in Section 8
of the Employment Agreement, which covenants shall remain in full force and effect following the Termination Date.

 

13.            Equitable
Relief. Executive acknowledges that a remedy at law for any breach or attempted breach of this Agreement will be inadequate,
and agrees that MDC shall be entitled to specific performance and injunctive and other equitable relief in the case of any such
breach or attempted breach. It is also agreed that, in addition to any other remedies, in the event of a breach of this Agreement
by Executive, MDC may withhold and retain all or any portion of the Severance Payments and/or Vesting Entitlements.

 

14.            Severability.
If any term or condition of this Agreement and Release shall be held to be invalid, illegal or unenforceable in any respect by
a court of competent jurisdiction, this Agreement and Release shall be construed without such term or condition. If at the time
of enforcement of any provision of this Agreement, a court shall hold that the duration, scope or area restriction of any provision
hereof is unreasonable under circumstances now or then existing, the parties hereto agree that the maximum duration, scope or area
reasonable under the circumstances shall be substituted by the court for the stated duration, scope or area.

 

15.           Choice
of Law. This Agreement and Release shall be construed
and enforced in accordance with, and governed by, the laws of the State of New York, without regard to its choice of law provisions.

 

    5

     

    

 

16.            Material
Non-Public Information. Executive acknowledges that he may be in possession of material non-public information about MDC,
and covenants not to trade in any MDC securities from and after the date hereof while in possession of material non-public information
or otherwise in violation of any applicable securities law or regulation.

 

17.            Indemnification.
Subject to Section 124 of the Canada Business Corporations Act (as amended or re-enacted from time to time and including the
regulations made pursuant thereto, the “Act”) or, if the Company domesticates to the State of Delaware, Section 145
of the Delaware General Corporation Law (as amended or re-enacted from time to time and including the regulations made pursuant
thereto, the “DGCL”), the
Company shall indemnify and hold harmless the Executive and his heirs, executors, administrators and other legal personal representatives
(each, an “Indemnitee”), to the maximum extent permitted by the Act (or as applicable the DGCL), from and against
(a) any liability and all costs, charges and expenses that an Indemnitee sustains or incurs in respect of any action, suit
or proceeding that is proposed, threatened or commenced against an Indemnitee for or in respect of anything done or permitted by
the Executive in respect of the execution of the duties of his office; and (b) all other costs, charges and expenses that
the Executive sustains or incurs in respect of the affairs of the Company. The Company shall also indemnify the Executive in such
other circumstances to the maximum extent as the Act (or as applicable the DGCL) permits or requires. To the extent permitted by
the Act (or as applicable the DGCL), the Company will advance or reimburse any expenses, including reasonable attorneys’
fees, incurred by an Indemnitee in investigating and defending any actual or threatened action, suit or proceeding for which an
Indemnitee may be entitled to indemnification under this Section 17.

 

18.            Amendment.
This Agreement and Release may not be amended or modified in any way, except pursuant to a written instrument signed by both parties.

 

***

 

    6

     

    

 

HAVING READ AND UNDERSTOOD THE RELEASE,
CONSULTED COUNSEL OR VOLUNTARILY ELECTED NOT TO CONSULT COUNSEL, AND HAVING HAD SUFFICIENT TIME TO CONSIDER WHETHER TO ENTER INTO
THIS AGREEMENT AND RELEASE, THE PARTIES HERETO HAVE EXECUTED THIS AGREEMENT AND RELEASE AS OF THE DAY AND YEAR FIRST WRITTEN BELOW.

 

	 	/s/
    Jonathan Mirsky
	 	Jonathan Mirsky
	 	 
	 	Dated: September 22, 2020
	 	 
	 	 
	 	MDC PARTNERS INC.
	 	 
	 	By: 	/s/ David Ross
	 	 	David Ross, Executive Vice President

 

    7

     

    

 

Exhibit A

 

Release of Claims

 

(i)      I,
Jonathan Mirsky, in consideration of and subject to the performance by MDC Partners Inc. (together with its subsidiaries, the “Company”),
of its material obligations under the Separation and Release Agreement with the Company, dated September __, 2020 (the “Agreement”),
do hereby release and forever discharge, as of the date hereof, the Company and its affiliates and its and all of their respective
present and former directors, officers, agents, representatives, employees, successors, assigns and direct or indirect owners (collectively,
the “Released Parties”) to the extent provided below. Defined terms used herein that are not otherwise defined
shall have the meanings set forth in the Agreement.

 

(ii)      I
have agreed that I will not receive the payments and benefits specified in Section 2 or 3 of the Agreement (A) unless
I execute this Release of Claims and do not revoke it within the time period permitted hereafter or (B) if I breach this Release
of Claims. I also acknowledge and represent that I have received all payments and benefits that I am entitled to receive (as of
the date hereof) by virtue of employment with the Company, other than as provided in the Agreement.

 

(iii)      Except
as provided in paragraph (v) below, I knowingly and voluntarily (for myself, my heirs, executors, administrators and
assigns) release and forever discharge the Company and the other Released Parties from any and all claims, lawsuits, controversies,
actions, causes of action, cross-claims, counter-claims, demands, debts, compensatory damages, liquidated damages, punitive or
exemplary damages, other damages, claims for costs and attorneys’ fees, or liabilities of any nature whatsoever in law and
in equity, both past and present (through the date of this General Release) and whether known or unknown, suspected, or claimed
against the Company or any of the Released Parties which I, my spouse, or any of my heirs, executors, administrators or assigns,
may have, which arise out of or are connected with my employment with, or my separation or termination from, the Company (including,
but not limited to, any allegation, claim or violation, arising under: Title VII of the Civil Rights Act of 1964, as amended; the
Civil Rights Act of 1991; the Age Discrimination in Employment Act of 1967, as amended (including the Older Workers Benefit Protection
Act); the Equal Pay Act of 1963, as amended; the Americans with Disabilities Act of 1990; the Family and Medical Leave Act of 1993;
the Civil Rights Act of 1866, as amended; the Worker Adjustment Retraining and Notification Act; the Employee Retirement Income
Security Act of 1974; any applicable Executive Order Programs; the Fair Labor Standards Act; or their state or local counterparts;
or under any other federal, state or local civil or human rights law, or under any other local, state, or federal law, regulation
or ordinance; or under any public policy, contract or tort, or under common law; or arising under any policies, practices or procedures
of the Company; or any claim for wrongful discharge, breach of contract, infliction of emotional distress, defamation; or any claim
for costs, fees, or other expenses, including attorneys’ fees incurred in these matters) (all of the foregoing collectively
referred to herein as the “Claims”); provided that the foregoing release shall not extend to, and in no event shall
the “Claims” which are being released hereunder include, (a) any rights to reimbursement or indemnification in
my capacity as an officer, director or employee of the Company or any of its Subsidiaries under the governing documents of the
Company or such Subsidiary, any reimbursement or indemnification agreement with the Company, any insurance policy or applicable
law, in accordance with the terms thereof, as a matter of law, or otherwise, or under any power that the Company may have to indemnify
me or hold me harmless, (b) my rights to payments or benefits due under Section 2 and Section 3 of the Agreement,
(c) my rights as a stockholder of the Company or (d) my rights to enforce the terms of this Release of Claims.

 

(iv)      I
represent that I have made no assignment or transfer of any right, claim, demand, cause of action, or other matter covered by paragraph
iii above.

 

    8

     

    

 

(v)      I
agree that this Release of Claims does not waive or release any rights or claims that I may have under the Age Discrimination in
Employment Act of 1967 which arise after the date I execute this Release of Claims. I acknowledge and agree that my separation
from employment with the Company shall not serve as the basis for any claim or action (including, without limitation, any claim
under the Age Discrimination in Employment Act of 1967).

 

(vi)      In
signing this Release of Claims, I acknowledge and intend that it shall be effective as a bar to each and every one of the
Claims hereinabove mentioned or implied. I expressly consent that this General Release shall be given full force and effect according
to each and all of its express terms and provisions, including those relating to unknown and unsuspected Claims (notwithstanding
any state statute that expressly limits the effectiveness of a general release of unknown, unsuspected and unanticipated Claims),
if any, as well as those relating to any other Claims hereinabove mentioned or implied. I acknowledge and agree that this waiver
is an essential and material term of this Release of Claims and that without such waiver the Company would not have agreed to the
terms of the Agreement. I further agree that in the event I should bring a Claim seeking damages against the Company, or in the
event I should seek to recover against the Company in any Claim brought by a governmental agency on my behalf, this Release of
Claims shall serve as a complete defense to such Claims. I further agree that I am not aware of any pending charge or complaint
of the type described in paragraph (iii) as of the execution of this Release of Claims.

 

(vii)      I
agree that neither this Release of Claims, nor the furnishing of the consideration for this Release of Claims, shall be deemed
or construed at any time to be an admission by the Company, any Released Party or myself of any improper or unlawful conduct.

 

(viii)      I
agree that I will forfeit all amounts payable by the Company pursuant to Section 2 and 3 of the Agreement if I challenge the
validity of this Release of Claims. I also agree that if I violate this General Release by suing the Company or the other Released
Parties, I will return all payments received by me pursuant to the Agreement.

 

(ix)      Whenever
possible, each provision of this Release of Claims shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Release of Claims is held to be invalid, illegal or unenforceable in any respect under any applicable
law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision or any
other jurisdiction, but this Release of Claims shall be reformed, construed and enforced in such jurisdiction as if such invalid,
illegal or unenforceable provision had never been contained herein.

 

    9

     

    

 

BY SIGNING THIS RELEASE OF CLAIMS, I
REPRESENT AND AGREE THAT:

 

(a)      I
HAVE READ IT CAREFULLY;

 

(b)      I
UNDERSTAND ALL OF ITS TERMS AND KNOW THAT I AM GIVING UP IMPORTANT RIGHTS, INCLUDING BUT NOT LIMITED TO, RIGHTS UNDER THE
AGE DISCRIMINATION IN EMPLOYMENT ACT OF 1967, AS AMENDED; TITLE VII OF THE CIVIL RIGHTS ACT OF 1964, AS AMENDED; THE EQUAL PAY
ACT OF 1963, THE AMERICANS WITH DISABILITIES ACT OF 1990; AND THE EMPLOYEE RETIREMENT INCOME SECURITY ACT OF 1974, AS AMENDED;

 

(c)      I
VOLUNTARILY CONSENT TO EVERYTHING IN IT;

 

I HAVE BEEN ADVISED TO CONSULT WITH AN
ATTORNEY BEFORE EXECUTING IT AND I HAVE DONE SO OR, AFTER CAREFUL READING AND CONSIDERATION, I HAVE CHOSEN NOT TO DO SO OF
MY OWN VOLITION; I HAVE HAD AT LEAST 21 DAYS FROM THE DATE OF MY RECEIPT OF THIS RELEASE OF CLAIMS SUBSTANTIALLY IN ITS FINAL FORM,
TO CONSIDER IT AND THE CHANGES MADE SINCE THE FINAL VERSION OF THIS RELEASE OF CLAIMS ARE NOT MATERIAL AND WILL NOT RESTART THE
REQUIRED 21-DAY PERIOD;

 

(d)      I
UNDERSTAND THAT I HAVE SEVEN DAYS AFTER THE EXECUTION OF THIS RELEASE OF CLAIMS TO REVOKE IT AND THAT THIS RELEASE SHALL NOT BECOME
EFFECTIVE OR ENFORCEABLE UNTIL THE REVOCATION PERIOD HAS EXPIRED;

 

(e)      I
HAVE SIGNED THIS RELEASE OF CLAIMS KNOWINGLY AND VOLUNTARILY AND WITH THE ADVICE OF ANY COUNSEL RETAINED TO ADVISE ME WITH RESPECT
TO IT; AND

 

(f)      I
AGREE THAT THE PROVISIONS OF THIS RELEASE OF CLAIMS MAY NOT BE AMENDED, WAIVED, CHANGED OR MODIFIED EXCEPT BY AN INSTRUMENT
IN WRITING SIGNED BY A REPRESENTATIVE OF THE COMPANY AND BY ME.

 

	 	 
		Jonathan Mirsky	

 

	DATE:	 	, 2020

 

    10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}]]